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2The work incorporated in the thesis with the title “STUDIES ON
HETEROCYCLIC COMPOUNDS” has been described as under.
[A] STUDIES ON PYRAZOLES
[B] STUDIES ON MICROWAVE INDUCED PYRAZOLINE
SYNTHESIS
[A] STUDIES ON PYRAZOLES
       Pyrazole nucleus represent one of the most important class of  compounds
possesing wide range of therapeutic activities such as antimicrobial, atitubercular,
hypnotic, anthelminetic, amoebicidal,  anticonvulsant, CNS   depressant, antitumor
and antithyroid. Pyrazole derivatives are also used as insecticidal and herbicidal.
Considering the increasing importance of pyrazole nucleus, we have
undertaken the synthesis of some novel chalcone, pyrimidinone, cyanopyridine,
cyanopyran, imidazolinone, barbitone, thiazolidinone, acetonitrile and pyrazoline
bearing 1N,3-diphenyl pyrazole nucleus.
PART - I    :   STUDIES ON  CHALCONES
Chalcones are phenylstyryl ketone containing reactive ethylinic group
(-CO-CH=CH-). Chalcone derivatives represent various biological   activities such
as  antibacterial, analgesic, anthelmintic, antiinflammatory, antitubercular, antifungal,
antimicrobial etc. These valid observation led us to synthesise some novel chalcone
derivatives, which have been described as under.
3SECTION - I   :   Synthesis and biological evaluation of  1-Aryl-3-(1’N,3’-
       diphenyl-4’-pyrazolyl)-2-propene-1-ones
Type ( I ) R = Aryl
     The chalcone derivatives of type (I) have been prepared by the  condensation of
1N,3-diphenyl-4-formyl-pyrazole with different  aryl ketones in presence of 40%
NaOH.
PART - II   :   STUDIES ON CYANOPYRIDINES
Cyanopyridine derivatives have attracted considerable attention in view of
their great therapeutic importance as anticonvulsant, antifungal,antibacterial,
antidiabetic and hypertensive agents. To approach these goal, preparation of some
novel cyanopyridine has been undertaken as under.
SECTION - I   :  Synthesis and biological evaluation of 1’N,3’-Diphenyl -4’-
      [2-amino-3-cyano-6-aryl-4-pyridyl]-pyrazoles











4The cyanopyridne derivatives of type (II) have been prepared by the reaction
of type (I) with malononitrile and ammonium acetate.
PART - III    :   STUDIES ON CYANOPYRANS
Pyran derivatives represants one of the modest classes of compounds
possessing wide range of therapeutic activities such as antimicrobial,antifungal,
antiviral, antifilarial and antisecretory. In view of these facts,  it was contemplated to
synthesise  some new pyrans, which have been described as under.
SECTION - I   :   Synthesis and biological evaluation of 1’N,3’-Diphenyl-4’-
       [2-amino-3-cyano-6-aryl-4-dihydropyranyl]-pyrazoles
Type(III) R=Aryl
The cyanopyran derivatives of type (III) have been prepared by the reaction
of type (I) with malononitrile in pyridine.
PART - IV    :   STUDIES ON  PYRAZOLINES
Pyrazoline derivatives are endowed with different therapeutic activities such
as antibacterial, analgesic, anthelmintic, antiinflammatory, antitubercular etc. These
valid observation led us to synthesise some novel pyrazoline derivatives bearing







5SECTION - I   :   Synthesis and biological evaluation of  3-Aryl-5-(1’N,3’-
       diphenyl-4’-pyrazolyl)-pyrazolines
Type(IV) R=Aryl
The pyrazoline derivatives of type (IV) have been prepared by the reaction of
type (I) with  hydrazine hydrate.
SECTION - II   :  Synthesis and biological evaluation of 1N-Phenyl-3-aryl-5-
      (1’N,3’-diphenyl-4’-pyrazolyl)-pyrazolines
Type(V) R=Aryl
The pyrazoline derivatives of type (V) have been prepared by the  reaction of









6PART - V    :   STUDIES ON PYRIMIDINONES
Pyrimidinone nucleus possess remarkable pharmaceutical importance  and
biological activity, some of the pyrimidinones, which occur as natural product, like
nucleic acids and vitamin B and can be used as therapeutic agent for the treatment of
AIDS and antitumor agents, keeping in association of pyrmidinones with varied
biological activity, it was thought worthwile to synthesise new pyrimidinone as under.
SECTION - I   :   Synthesis and biological evaluation of 6-Aryl-4-(1’N,3’-
       diphenyl-4’-pyrazolyl)-1,2,3,4-tetrahydropyrimidin-2-ones
        Type (VI )      R = Aryl
The pyrimidinone derivatives of type (VI) have been prepared by the
reaction of type (I) with urea  in presence of acidic catalyst like HCl.
SECTION - II   :   Synthesis and biological evaluation of 5-Alkyl- 6-alkyl/
                   aryl-4-(1’N,3’-diphenyl-4’-pyrazolyl)-1,2,3,4-
         tetrahydropyrimidin-2-ones












7The pyrimidinone derivatives of type (VII) have been prepared by the
reaction of 1N,3-diphenyl-4-formyl-pyrazole, urea with different 1,3-diketones in
presence of acidic catalyst like HCl in methanol.
PART - VI    :   STUDIES ON BARBITONES
Barbitone derivatives have been found to be biological activities viz.
anticonvulsant, hypnotic, sedative and antiinflammatory.  Promoted by above facts,
some new barbitones have been prepared as under.
SECTION - I   :   Synthesis and biological evaluation of 5-[1’-Aryl-3’-(1”N,3”
     -diphenyl-4”-pyrazolyl)-prop-2’-enylidine]-barbituric acids
     Type (VIII)           R = Aryl
The barbitone derivatives of type (VIII) have been prepared by the   reaction
of  type (I) with barbituric acid in glacial acetic acid.
PART - VII    :   STUDIES ON IMIDAZOLINONES
Imidazolidinone derivatives have been found to be potent drug in
pharmaceutical and possess a wide range of biological activities such as
anticonvulsant, sedative, hypnotic, antiinflammatory, antihistamine and   antithyroid.
In order to develop medicinally important compounds,   we have  synthesised some








8SECTION - I   : Synthesis and biological evaluation of 1N-Aryl-2-alkyl/
aryl-4-(1’N,3’-diphenyl-4’-pyrazolylmethino)-imidazolin-
5-ones
    Type (IX)     R1=Aryl     R2 = Alkyl / Aryl
The imidazolinone derivatives of type (IX)  have been prepared by the
reaction of azalactone with different aryl amine in pyridine.
PART - VIII    :   STUDIES ON 4-THIAZOLIDINONES
Compounds bearing thiazolidinone nucleus show wide range of     biological
activity such as antimicrobial, CNS depressant, antiinflammatory, antitubercular,
sedative, anticonvulsant, analgesic and antihypertensive. By considering these valid
observations, we have synthesised some new thiazolidinones  which have been
described as under.
SECTION - I   :   Synthesis and biological evaluation of 2-Arylimino- 3N-aryl
     -5-(1’N,3’-diphenyl-4’-pyrazolylmethino)- 4- thiazolidinones













9The thiazolidinone derivatives of type (X) have been undertaken by the
condensation of 1N,3-diphenyl-4-formyl-pyrazole with different thiazolidinones in
glacial acetic acid.
PART - IX    :   STUDIES ON NITRILES
 Recently substituted nitrile derivatives have drawn considerable attention due
to their good pharmacological activities like cardiovascular, sedative, antifungal and
antibacterial. By considering these valid observations, we have synthesised some
new nitriles which have been described as under.
SECTION - I   :   Synthesis and biological evaluation of α-Arylamino-(1’N,3’
       -diphenyl-4’-pyrazolyl)-acetonitriles
      Type ( XI )     R = Aryl
The nitriles of type (XI) have been prepared by the condensation of
1N,3-diphenyl-4-formyl-pyrazole with different aromatic amines by the presence of






[B]    STUDIES ON MICROWAVE INDUCED PYRAZOLINES SYNTHESIS
In the recent year, MORE (Microwave Induced Organic Reaction
Enhancement) technique has become very popular due to substantial reduction in
reaction time, operational time, operational simplisity and formation of clear
reaction products. Keeping this in view, we investigated the synthesis of the pyrazolines
using microwave irradiation and also by conventional method.
PART - I    :   STUDIES ON  PYRAZOLINES BY CONVENTIONAL AND
 MICROWAVE INDUCED SYNTHESIS
Pyrazoline derivatives are endowed with different therapeutic activity such as
antibacterial, analgesic, anthelmintic, antiinflammatory, antitubercular etc. This valid
observation led us to synthesise some novel pyrazolines bearing  pyrazole     moiety,
which have been described as under.
SECTION - I   :  Synthesis and biological evaluation of 1N-Acetyl-3-aryl-5-
      (1’N,3’-diphenyl-4’-pyrazolyl)-pyrazolines by conventional
      method
           Type (XII)        R = Aryl
The pyrazoline derivatives of type (XII) have been prepared by the reaction








SECTION - II   :  Synthesis and biological evaluation of 1N-Acetyl-3-aryl-5-
       (1’N,3’-diphenyl-4’-pyrazolyl)-pyrazolines by microwave
       method
         Type (XIII)         R = Aryl
The pyrazoline derivatives of type (XIII) have been prepared by the reaction
of type (I) with  hydrazine hydrate and glacial acetic acid under microwave
irradiation in few minutes.
The constitution of the synthesised product have been characterised using
elemental analysis, infra red and 1H nuclear magnetic resonance spectroscopy and
further supported by mass spectrometry. Purity of all the compounds have been
checked by thin layer chromatography.
in vitro studies on multiple biological activities.
(I) All the compounds have been evaluated for their in vitro biological assay like
antitubercular activity towards a strain of Mycobacterium tuberculosis H37Rv
at a concentration of 6.25 µg/ml  using Rifampin as  standard  drug, which have









(II) All the compounds  have been also  evaluated  for their antibacterial activity
towards Gram positive and Gram negative bacterial strains and antifungal
activity  towards  Aspergillus  niger at  a  concentration  of  40µg/ml. The
biological activity of the synthesised compounds have been compared with
standard drugs.
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Heterocyclic chemistry has seen unparalled progress owing to their wide
natural occurance, specific chemical reactivity and broad spectrum utility.
Heterocyclic compounds have great applicability in pharmaceutics because
they have specific chemical reactivity and provides false synthons in biosynthetic
process or block the normal functioning of biological receptors. The inhibition
of amide resonance resulting into more susceptibility of β-lactam to nucleophile
is considered at least in part responsible for antibacterial property, apparently
by acetylating transpeptidase and thus inhibiting bacterial cell wall biosynthesis.
Most of the alkaloids which are nitrogenous bases occuring in plants and
many antibiotics including penicillin and streptomycin have also heterocyclic
r ing system. Many natural  pigments such as indigo, haemoglobin and
anthocyanin are heterocycles. Most of the sugars are their derivatives including
Vitamin C for intance, exist largely in the form of five membered. Vitamin B6
(Pyridoxine) is a derivative of pyrimidine essential in aminoacid metabolism.
Important drugs, poisons and medicines (both natural and synthetic) such as
sulphathiazole, pyrenthrin, rotenmone, strychnine, reserpine, certain of the
antihistaminics, the ergot alkaloids caeffine, cocaine, barbiturates, etc. are
heterocyclic compounds.
Heterocyclic compounds have great biological significance because :
1. They have a specific chemical reactivity.
2. They resemble essential metabolism and can also provide false synthons
in biosynthetic process.
12
3. They fit receptors and block their normal working.
4. They provide convenient building blockers to which biologically active
substituents can be attached.
The interesting biological activities of heterocycles have stimulated
considerable research work in recent years including to the synthetic utility.
Heterocyclic compounds can be synthesised by cyclisation reactions
(accompanied by elemination of small molecules), addition reactions (adduct
formation), ring transformation reactions or replacement involving groups.
Formation of heterocycle from acyclic compounds alters the reactivity. Piperidine
is reactive than ethyl propylamine due to the reduction in steric incumbrance of
the nitrogen lone pair.
AIMS AND OBJECTIVES
In the pharmaceutical field, there is a need for new and novel chemical
inhibitors of biological functions. Our efforts are focused on the introduction of
chemical diversity in the molecular frame work in order to synthesising
pharmacologically interesting heterocyclic compounds of widely different
composition.
During the course of research work looking to the applications of
heterocyclic compounds, several entities have been designed, generated and
characterised using spectral studies. The aims and objectives of the work carried
out are as under.
1. To synthes i se  pharmaco log ica l ly  ac t ive  ent i t ies  l i ke  cha lcones ,
cyanopyridines, cyanopyrans, pyrazolines, pyrimidinones, barbitones,
imidazolinones, thiazolidinones and nitriles bearing 1N, 3-diphenyl pyrazole
nucleus.
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2. To characterise these products for structural elucidation using spectroscopic
techniques like IR, PMR and Mass spectral studies.
3. To check the purity of all compounds using thin layer chromatography.
4. To evaluate these new products for better drug potential against different
strains of bacteria, fungi and for antitubercular activity.
The research work is presented as studies on [A] Pyrazoles and [B]
Microwave induced pyrazolines synthesis.
In  a  programmed research d i rec ted towards  the cons t ruc t ion of
therapeutically active new heterocycles bearing 1 N, 3-diphenyl pyrazole nucleus
has been investigated in following parts.
[A] : STUDIES ON PYRAZOLES
PART - I : STUDIES ON CHALCONES
PART - II : STUDIES ON CYANOPYRIDINES
PART - III : STUDIES ON CYANOPYRANS
PART - IV : STUDIES ON PYRAZOLINES
PART - V : STUDIES ON PYRIMIDINONES
PART - VI : STUDIES ON BARBITONES
PART - VII : STUDIES ON IMIDAZOLINONES
PART - VIII : STUDIES ON THIAZOLIDINONES
PART - IX : STUDIES ON NITRILES
[B] : STUDIES ON MICROWAVE INDUCED PYRAZOLINES
PART - I : SYNTHESIS AND BIOLOGICAL EVALUATION OF
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The pyrazole ring system (I) consists of a doubly unsaturated five membered
ring containing two adjacent nitrogen atoms. Knorr1,2 first synthesised a
compound containing this system in 1883 by a reaction of ethylacetoacetate
with phenylhydrazine which yield 1-phenyl-3-methyl-5-pyrazolone (II).
Knorr3 introduced the name pyrazole for these compounds to donate that
the nucleus was derived from pyrrole by replacement of carbon by nitrogen;
since many durgs and dyes contain the pyrazole nucleus, the class has been
widely studied and the field continuous to be active today even though antipyrine
and related medicine no longer in common use. Pyrazolone dyes are especially
important in colour photography.
SYNTHETIC ASPECT
Various methods for the preparation of pyrazoles have been cited in
literature.
1. The reaction of hyrazine or its derivatives such as alkyl or aryl hydrazines,



















2. The reaction of hydrazines with α, β-unsaturated carbonyl compounds.
3. The reaction of aliphatic diazo compounds such as diazomethane or
diazoester with acetylene or olefins.
THERAPEUTIC IMPORTANCE
Much research has been carried out with the aim to finding therapeutic
values of pyrazole moiety since their discovery. A large number of substituted








8. p-38 Kinase inhibitors15-18
9. Antiepilectic19
10. Nemeticidal20
Havaldar Freddy et. al.21 synthesised 4,5-dihydro-3-phenyl-1H-pyrazole
and reported their biological activity. Carbau Romuald and co-worker22 have
prepared pyrazole derivatives useful as reverse transcriptase inhibitors for the











Someya Shinzo and co-worker23 have synthesised pyrazole derivatives
and repor ted their herbicidal activity. Gehring Reinhold et. al. 24 have
synthesised 5-Amino-4-cyano-1-aryl-pyrazoles and shown them as plant growth
inhibitors. Nakamura Katsyya and co-workers25,26 have prepared 1,5-diphenyl
pyrazoles as Cox-II inhibitors.
Jansen Karte et. al.27 have synthesised pyrazole derivatives as pesticides.
Feid-Al lah Hassan28 have prepared pyrazoles and repor ted their
antidiabetic and antibacterial activity. Ejima Akio et. al.29 have synthesise
pyrazole derivatives as antitumor agents.
Banks Bernard et. al.30 have synthesised pyrazole derivatives (VII) and
























Schindler Ursula et. al.31 synthesised new pyrazole derivatives (VIII) as
cardiovascular agents.
Pier Giovanni Baraldi et. al.32 synthesised pyrazole derivatives as
antileukemic agents. Thomas Alan Crowell et. al.33 prepared new pyrazoles as
selective β3 adrenergic agonists. Kevin M. Moore et. al.
34 prepared pyrazoles
as human dopamine-D4-receptors. Grazid Mamolo et. al.35 have newly
synthesised pyrazole derivatives tested for antimicrobial activity. R. V. Huang
and co-worker36 have prepared some 1,2,4-triaryl-4-alkyl-pyrazoles as estrogen
receptor. C. Vittoria and co-worker37 have prepared some pyrazoles as adinosine
receptor antagonists.
Recently,Atkinson R. N. et. al.38 have synthesised pyrazoles as sodium
channel blocker (IX). Murakanli Hiroshi et. al.39 have synthesised pyrazoles as
antifouling agent. Gelliber t Francoise et. al.40 have synthesised pyrazole

















Laborde Edgardo et. al.41 have found that pyrazoles possess glycine
transporter-2 inhibitor activity. Andrew Thurkaub et. al.42 have synthesised high
affinity C5a receptor modulator pyrazoles. Nagaaki Sato et. al.
43 have prepared
pyrazoles as neuropeptide T5 receptor antagonists. G. M. B. Hi Yamanouch
Pharma Co. 44  has prepared pyrazoles as glycine transporter protein inhibitor
(X).
Jacques Dumas and co-workers45 have prepared pyrazole derivatives as
rafkinase and angiogenesis inhibitor agents. David L. S. et. al.46 have synthesised
pyrazoles as activators of the nitrile oxide receptor and soluble guanglate cyclase
agent. T Van Herk et. al. 47 have synthesised pyrazoles as nicotinic acid receptor
(XI). Barber Christopher et. al.48 have synthesised pyrazole derivatives as
phosphidiesterase inhibitors. Nishimura Tsoshihiro et. al.49 have synthesised






















Recently, it is found that pyrazole derivatives possesses a number of
biological activities such as fungicidal50,51, herbicidal52-55, cardiovascular56,
antiinflammatory57-59, Cox-II inhibitor60, antimicrobial61, anticancer62-64,
protein kinase inhibitor65-68, antibacterial69,70, antiviral71, antiparasitic72,
HIV reverse transcriptase inhibitor73,74 and 5-H T20 receptors
75-77.
Literature survey reveals that the compounds bearing pyrazole moiety in
general passage potential drug activity. Looking to the diversified biological
activity, it appeared of interest to synthesise some chalcones, cyanopyridines,
cyanopyrans,  pyrazol ines,  pyr imidinones,  barbi tones,  imidazol inones,
thiazolidinones and nitriles bearing pyrazole moiety, in order to achieving
compounds having better therapeutic importance. These study are described in
following parts.
[A] : STUDIES ON PYRAZOLES
PART - I : STUDIES ON CHALCONES
PART - II : STUDIES ON CYANOPYRIDINES
PART - III : STUDIES ON CYANOPYRANS
PART - IV : STUDIES ON PYRAZOLINES
PART - V : STUDIES ON PYRIMIDINONES
PART - VI : STUDIES ON BARBITONES
PART - VII : STUDIES ON IMIDAZOLINONES
PART - VIII : STUDIES ON THIAZOLIDINONES
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The chemistry of chalcones have generated intensive scientific studies
throughout the world, specially interesting are their biological and industrial
applications. Chalcones are coloured compounds because of the presence of
the chromophore, auxochromes. They are known as benzalacetophenones or
benzyl idene acetophenones. Kostanecki and Tambor78 gave the name
"chalcone".
Chalcones are characterised by their possession of a structure in which
two aromatic rings A and B are linked by an aliphatic three carbon chain.
The alternative names given to chalcones are phenyl styryl ketones,
benzalacetophenone, β-phenyl acrylphenone, γ-oxo-α,γ-diphenyl-α-propylene
and α-phenyl-β-benzoethylene.
SYNTHETIC ASPECT
A considerable variety of methods are available for the synthesis of
chalcones. The most convenient method is one that involves the Claisen-Schmidt
condensation of equimolar quantities of an ary methyl ketones with arylaldehyde





Several condensing agents used are alkali of different strength80,81,
hydrogen chloride82,83, phosphorous oxychloride84, piperidine85, anhydrous
aluminium chloride86, boron trifluoride87, aq. solution of borax88, amino
acids89 and perchloric acid90 etc.
MECHANISM
Chalcone formation proceeds through Aldol type of condensation and the
process is catalysed by the presence of alkali91. Following are the steps of the
reaction mechanism.
The intermediate Aldol type of products formed readily undergoes
dehydration even under mild condition, particularly when R and R' are aryl
groups.
REACTIVITY OF CHALCONES
The chalcones have been found to be useful for the synthesis of variety of
heterocyclic compounds are as under.
a. Pyrazolines92 and its derivatives can be prepared by the condensation of
chalcones with hydrazine hydrate and acetic acid.
(i) CH
3










(iii) R' – C+         +    –CH
2
CO – R                 R' – C – CH
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(iv) R' – C – CH
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(v) R' – C – CH
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b. Chalcones on condensation with malononitrile and ammonium acetate
yields 2-amino-3-cyano pyridines93.
c. Isoxazoles94 can be prepared by the treatment of chalcones with
hydroxylamine hydrochloride and sodium acetate.
d. Chalcone on condensation with malononitrile in pyridine forms 2-amino-
3-cyanopyrans95.
e. Cha lcones  on t rea tment  wi th  urea  in  presence o f  a lka l i  a f fords
2-oxopyrimidines96.
f. Chalcones on reaction with thiourea in presence of alkali/acid yields
2-thienopyrimidines97.
g. Chalcones on treatment with guanidine hydrochloride in presence of alkali
affords 2-amino pyrimidines98.
h. Chalcones reacts with P2S5 yielding 2-isothiazolines
99.
i. Chalcones with sodium nitrile in presence of glacial acetic acid in ethanol
produces 2-1H-pyrimidines100.
j. Chalcones with monoethanolamine in ethanol gives 1,4-oxazipines101.
k. Cha lcones  wi th  2-amino th iophenol  in  ace t i c  ac id  produces
1,5-thiazepines102.
l. Chalcones on reaction with semicarbazide hydrochloride in ethanol affords
1-carboxamide pyrazolines103.
m. Chalcones on reaction with 2-aminopyrimidine in glacial acetic acid affords
pyrido pyrimidines104.
n. Oxiran105 can be prepared by the reaction of chalcone with H2O2 in basic
media.
o. Cyanopyridone106 derivatives can be prepared by the condensation of
chalcone with ethylcyanoacetate.
p. Chalcones on reaction with barbituric acid gave barbitone107 derivatives.




Chalcones are potential biocides, some naturally occuring antibiotics and















Moreover, synthesis and antibacterial activity of substituted chalcone
derivatives have been reported by Modi et. al.127 and Attia A128, V. Mudalir
et. al.129 have prepared phenoxychalcones and observed their insecticidal
activity. Kammei et. al.130 have synthesised chalcone derivatives having
antitumor activity. De Vincenzo et. al.131 and Han et. al.132 have reported
chalcone derivatives for their antiinflammatory activity.
Aldose reductase inhibitor activity of chalcone derivatives have been
reported by Okuyama et. al.133. They are also associated with antitumor and
antifungal activity as reported by Tsotitus and co-worker134. Antifeedant activity
of chalcones have been observed by Sarma and Sreenivasulu135.
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Ezio Bombardelli et. al. 136 have demonstrated that chalcone possess a
valuable antiproliferation activity both on sensitivie cancereous cell and on cell
which are resistant to common chemotherapeutic drugs. Some of the chalcones
have been patented for their use for treatment of glaucoma137 and showed
ant i fungal  138,139 aldose reductase inhibi tor140, ant icancer141 and
antimicrobial 142,143 activities.
Recently, Ni Liming et. al.144 have synthesised chalcones and screened
for their antiinflammatory and cardiovascular activity (II). Kumar Srinivas et.
al.145  have synthesised chalcones as a antitumor agent.Ko Horng-Huey et.
al.146 have prepared chalcones as antiinflammatory agent. Nakahara Kazuhiko
et. al.147  have synthesised chalcones as carcinogen inhibitors. Antitubercular
agents of chalcone derivatives have been prepared by Lin Yuh-Meei et. al.148.
Das B. P. et. al.149 have found that chalcones possesses larvicidal
properties. Kim Min-Young et. al.150 have synthesised chalcones and tested for










Liu Mei et. al.151 have prepared antimalarial chalcones. Opletalova
Veronika et. al.152 have synthesised chalcones and screened as cardiovascular
agents.
Moreover, it has been found that chalcone derivatives possesses nitric oxide
inhibitor (IV)153,154, anti-HIV155,156 and antiproliferative 157,158 (V)
activities.
Chalcone bearing a very good synthon, variety of novel heterocycles with
good pharmacological profile can be designed. These valid observation led us
to explore chalcone chemistry by synthesising several derivatives like cyano
pyrans, cyanopyridines, pyrazolines, pyrimidinones and barbitones bearing
different heterocyclic ring systems for medicinal value, in order to achieving
better therapeutic agents, this study described as under.
SECTION - I : SYNTHESIS AND BIOLOGICAL EVALUATION OF 1-











R1-R7  = H, OH, OMe
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 1-ARYL-3-[1'N, 3'-
DIPHENYL-4'-PYRAZOLYL]-2-PROPENE-1-ONES
Recently much interest has been focoused on the synthesis and biodynamic
activities of chalcones and it is a good synthon for various heterocyclic rings.
With a view to obtained compounds having better therapeutic activity, we have
synthesised 1-Aryl-3-(1'N,3'-diphenyl-4'-pyrazolyl)-2-propene-1-ones by the
condensation of 1N,3-Diphenyl-4-formyl-pyrazole with various aromatic ketones.
The constitution of the synthesised products have been characterised by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and mass spectrometry also. In mass spectrometry the m/z value
indicate the molecular weight, i.e. when R=p-Anisyl, molecular weight=380,
m/z=381 (m+1)
All the compounds have been also evaluated for their antibacterial activity
towards Gram positive and Gram negative bacterial strains and antifungal activity
towards Aspergillus niger at a concentration of 40µg/ml. The biological activity
of the synthesised compounds have been compared with standard drugs. Some
compounds have been found to have good and equivalent activity as compared
to the known antibiotics recorded on Page No.38.
Moreover, some selected compounds have been evaluated for their in vitro
biological assay towards a strain of Mycobacterium tuberculosis H37Rv at a
concentration of 6.25 µg/ml using Rifampin as a standard drug which have been
tested at Tuberculosis Antimicrobial Acquisition Co-ordinating Facility (TAACF),
Alabama, U. S. A.







































IR SPECTRAL STUDY OF 1-p-ANISYL-3-[1'N,3'-DIPHENYL-4'-PYRAZOLYL]-2-PRO-
PENE-1-ONE
I
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C-H str. (sym.) 2929 2975-2950 670
C–H def. (asym.) 1446 1470-1435 ''
C–H def. (asym.) 1353 1385-1370 ''
 Aromatic C-H str. 3060 3090-3030 670
C=C str. 1507 1520-1480 ''
C–H i.p.def. 1112 1125-1090 "
α−β− -C=O str. 1658 1700-1640 673
unsaturated
Ketone -CH=CH str. 1502 1644-1618 "
Ether C-O-C str. (asym) 1218 1260-1220 671
C-O-C str. (sym) 1031 1075-1020 "













































PMR SPECTRAL STUDY OF 1-(p-ANISYL)-3-[1'N,3'-DIPHENYL-4'-PYRAZOLYL]-2-
PROPENE-1-ONE
Internal Standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity Inference J Value
No. (δ ppm) of Protons In Hz
1 3.88 3H singlet Ar-OCH3 -
2 6.92-6.97 2H doublet CHhh' J=8.9
3 7.3-7.4 2H doublet CHjk -
4 7.4-7.5 5H multiplate CHa -
5 7.7-7.73 2H doublet CHbf -
6 7.75-7.8 2H doublet CHce -
7 7.9 1H doublet CHd -
8 7.94-8.0 2H doublet CHgg' J=8.9








































































































m/z = 128 m/z = 178
m/z = 135
BASE PEAK





Gram positive bacteria : Staphylococcus aureus
Bacillus Megaterium
Gram negative bacteria : Proteus Vulgaris
Escherichia Coli
Fungi : Aspergillus niger
Concentration : 40µg
Solvent : Dimethyl formamide
Standard drugs : Ampicillin, Amoxicillin, Norfloxacin,
Penicillin, Greseofulvin
The antimicrobial activity was compared with standard drug viz Ampicillin,
Amoxicillin, Norfloxacin, Penicillin and antifungal activity was compared with
viz Greseofulvin. The inhibition zones measured in mm.
ANTITUBERCULAR ACTIVITY
The antitubercular evaluation of the compounds was carried out at
Tuberculosis Antimicrobial Acquisition Co-ordinating Facility (TAACF) U.S.A.
Method : BACTEC 460 Radiometric system.
Bacteria : Mycobacterium Tuberculosis H37Rv
Concentration : 6.25 µg/mg.
Standard drug : Rifampin.
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 1-ARYL-3-[1'N-3'-
DIPHENYL-4'-PYRAZOLYL]-2-PROPENE-1-ONES
[A] Synthesis of N-Phenylamino-α-methyl-phenyl azomethine
A mixture of phenylhydrazine (1.08g, 0.01M) and acetophenone (1.20g,
0.01M) in absolute ethanol was refluxed in waterbath for 4 hrs. in presence of 1
ml glacial acetic acid. Product obtained after cooling was crystallised from
absolute ethanol. Yield, 1.8 g (90%),  m.p.64oC. (C14H14N2 ; Requires :
C, 80.00 ; H, 6.66; N,13.37%; found; C, 79.92; H, 6.60; N,13.30%).
[B] Synthesis of 1N,3-Diphenyl-4-formyl pyrazole
N-Phenylamino-α-methyl-phenyl azomethine (0.84 g, 0.004 M) was added
in a mixture of Vilsmeier-Haack reagent (prepared by dropwise addition of 1.2ml
POCl3 in ice cooled 10 ml DMF) and refluxed for 6 hrs. The reaction mixture
was poured into crushed ice followed by neutralization using sodium bicarbonate.
Crude product was isolated and crystallized from methanol.          Yield, 2.16 g
(87%),  m.p. 125oC. (C
16
H12N2O; Requires ; C, 77.42; H, 4.84; N, 11.29%;
found : C, 77.38; H, 4.80; N, 11.23%).
[C] Synthesis of 1-(p-Anisyl)-3-[1'N,3'-diphenyl-4'-pyrazolyl]-2-propene-
1-one
To a well stirred solution of 1,N-3-Diphenyl-4-formyl pyrazole (2.48 g, 0.01
M) and p-methoxyacetophenone (1.5 g, 0.01 M) in ethanol (25 ml), 40% NaOH
added till the solution become basic. The reaction mixture was stirred for 24
hrs. The contents were poured into ice, acidified, filtered and crystallized from
ethanol. Yield, 3.57 g (94%), m.p.102oC. (C25H20N2O2 ; Requires : C, 78.95;
H, 5.26; N, 7.36%; found : C,78.92; H, 5.20; N, 7.32%). TLC solvent system
Acetone : Benzene (1:9).
Similarly other substituted chalcones have been prepared. The physical
data are recorded in Table No. 1.
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[D] Antimicrobial and antitubercular activity of 1-Aryl-3-[1'N,3'-
diphenyl-4'-pyrazolyl]-2-propene-1-ones
All the compounds have been evaluated for antimicrobial and antitubercular
activity as described under.
(a) Antimicrobial activity
It was carried out buy cup-plate diffusion method which has been described
as under.
(I) Antibacterial activity
The purified products were screened for their antimicrobial activity. The
nutrient agar, both prepared by the usual method, was inoculated aseptically
with 0.5 ml of 24 hrs. old subcultures of B. megaterium, S. aureus, E. coli
and P. valgaris in separate conical flasks at 40-50oC and mixed well by gentle
shaking. About 25 ml content of the flask were poured and evenly spreaded in
a petridish. (13 cm in diameter) and allowed to set for 2 hrs. The cups (10 mm
in diameter) were formed by the help of borar in agar medium and filled with
0.04 ml (40 µg) solution of sample in DMF.
The plates were incubated at 37oC for 24 hrs. and the control was also
maintained with 0.04 mole of DMF in a similar manner and the zones of inhibition
of bacterial growth were measured in millimeter and are recorded in Graphical
Chart No. 1.
(II) Antifungal activity
A. niger was employed for testing antifungal activity using cup-plate
method. The culture was maintained on Sabouraud's agar slants. Sterilised
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Sabouraud's agar medium was inoculated with 72 hrs. old 0.5 ml suspension of
fungal spores in a separate flask. About 25 ml of the inoculated medium was
evenly spreaded in a petridish and allowed to set for two hrs. The plates were
incubated at 30oC for 48 hrs. After the completion of incubation period, the
zones of inhibition of growth in the form of diameter in mm was measured.
Along the test solution in each petridish one cup was filled with solvent which
act as control. The zone of inhibition are recorded in Graphical Chart No. 1.
(b) Antitubercular activity
The antitubercular evaluation of compounds was carried out at Tuberculosis
Antimicrobial Acquisition Co-ordinating Facility (TAACF), U.S.A. Primary
screening of the compounds for antitubercular activity have been conducted  at
6.25 µg/ml towards Mycobacterium Tuberculosis H37Rv in BACTEC 12B
medium using the BACTEC 460 radiometr ic  sys tem. The compounds
demonstrating atleast >90% inhibition in the primary screen have been retested
at lower concentration towards Mycobacterium Tuberculosis H37Rv to
determine the actual minimum inhibitory concentration (MIC) in the BACTEC
460.
The antitubercular activity data have been compared with standard drug
Rifampin at 0.25 µg/ml concentration and it showed the 98% inhibition.






















1a C6H5- C24H18N2O 350 111 0.53 92 7.99 7.94
1b 4-Br-C6H4- C24H17N2OBr 429 150 0.56 94 6.53 6.56
1c 4-Cl-C6H4- C24H17N2OCl 384.5 105 0.58 88 7.28 7.23
1d 4-F-C6H4- C24H17N2OF 368 144 0.54 86 7.60 7.58
1e 4-CH3-C6H4- C25H20N2O 364 120 0.50 90 7.69 7.67
1f 4-OCH3-C6H4- C25H20N2O2 380 102 0.45 94 7.36 7.32
1g 2-OH-C6H4- C24H18N2O2 366 229 0.60 78 7.65 7.63
1h 4-OH-C6H4- C24H18N2O2 366 251 0.61 75 7.65 7.62
1i 4-NH2-C6H4- C24H19N3O 365 215 0.52 95 11.50 11.43
1j 3-NO2-C6H4- C24H17N3O3 395 168 0.57 90 10.63 10.67
1k 4-NO2-C6H4- C24H17N3O3 395 103d 0.51 92 10.63 10.64
1l 2-C4H3O- C22H16N2O2 340 160 0.55 70 8.23 8.25
1m 2-C4H3S- C22H16N2OS 356 178 0.61 76 7.86 7.83

































B.mega 14 11 17 11 23 13 14 12 15 13 19 20 11 23 22 24 25 0
s.aureus 17 12 15 20 15 11 13 16 14 16 19 12 21 22 23 17 24 0
E.coli 20 17 18 13 11 12 15 22 15 11 14 18 19 21 21 23 19 0
P.vulgaris 13 19 15 17 16 16 17 14 18 15 17 12 11 15 18 17 20 0
A.niger 15 12 17 13 16 18 15 19 20 20 18 21 13 0 0 0 0 25










COMPARATIVE STUDY OF ANTIMICROBIAL ACTIVITY WITH KNOWN ANTIBIOTICS
[A]
PART-I
Section - I : Antimicrobial activity of 1-Aryl-3-[1'N,3'-diphenyl-4'-pyrazolyl]-2-propene-1-ones
1e (23) 1d (20) 1a (20) 1b (19) 1i (20)
1l (20) 1k (19) 1h (22) 1i (18) 1j (20)
1m (21) 1m (19) 1l (21)
Ampicillin 23 22 21 15 -
Amoxicillin 22 23 21 18 -
Norfloxacin 24 17 23 17 -
Penicillin 25 24 19 20 -
Greseofulvin - - - - 25
B. mega S. aureus E. coli P. vulgaris A. niger
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity
Zone of inhibition in m.m.
3
9
TABLE NO. 1a : DATA OF IN VITRO EVALUATION OF ANTITUBERCULAR
ACTIVITY
TAACF, Southern Research Institute Dr. A. R. Parikh
Primary Assay Summary Report Saurashtra University
Sample Corp Where,R= Supplier Assay MTb MIC % comment
ID ID Strain µg/ml Inhib
162336 SHI-8 4-OH-C6H4- Sau.uni Alamar H37Rv >6.25 92
162341 SHI-13 2-C4H3S- Sau. uni. Alamar H37Rv >6.25 58 "
162337 SHI-9 4-NH2-C6H4- Sau.uni Alamar H37Rv >6.25 56  ''
162340 SHI-12 2-C4H3O- Sau.uni Alamar H37Rv >6.25 52  ''
162335 SHI-7 2-OH-C6H4- Sau.uni Alamar H37Rv >6.25 44  ''
162334 SHI-6 4-OCH3-C6H4- Sau.uni Alamar H37Rv >6.25 41  ''
162338 SHI-10 3-NO2-C6H4- Sau.uni Alamar H37Rv >6.25 33  ''
162330 SHI-2 4-Br-C6H4- Sau.uni Alamar H37Rv >6.25 20  ''
162332 SHI-4 4-F-C6H4- Sau.uni Alamar H37Rv >6.25 18  ''
162331 SHI-3 4-Cl-C6H4- Sau.uni Alamar H37Rv >6.25 14  ''
162339 SHI-11 4-NO2-C6H4- Sau.uni Alamar H37Rv >6.25 14  ''
162333 SHI-5 4-CH3-C6H4- Sau.uni Alamar H37Rv >6.25 5  ''
162329 SHI-1 C6H5- Sau.uni Alamar H37Rv >6.25 0 "
NIAID/ Southern Research institute/ GWL Hansen's Center/
Colorado state university proprietary information.
MIC Ri fampin
= 0.025mg/ml
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Pyridine, nucleus has been extensively explored for their applications in
the f ield of medicine, agriculture and industr ial  chemistry. Pyridine-3-
carboxamide occurs as a component of the structure of the important coenzymes
NADP+(I), one of the B2 complex of vitamins, occurs in red blood corpuscles
and participates in biochemical redox reaction. Pyridoxol (Vitamin B6) (II), occurs
in yeast and wheatgerm is an important food additive.
The availability of 3-cyanopyridine, nicotinamide and nicotinic acid make
possible their use as synthetic intermediates.
SYNTHETIC ASPECT
Different method for preparation of 3-cyano-pyridines are available in


























(I) R =  PO(OH)2
(II)
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1. Sakurai and Midorikaw167,168 have reported that malononitrile reacts
with α,β-unsaturated ketones to give 2-amino-3-cyano-4,6-disubstituted
pyridines (III).
MECHANISM
The reaction proceeds through conjugated addition of active methylene
compounds to the α,β-unsaturated system as shown below.
THERAPEUTIC IMPORTANCE
Cyanopyridine have attracted considerable attention as they appeared of
interest to possess antibacterial, anticholestermic, antifungal, antihypertensive
and antidiabetic activities. Thiele Kurt et. al.169 have studied the analgesic
activity of substituted 3-cyanopyridines. N. Latif and co-workers170 have
reported the antibacterial and antifungal activity of 2-amino-3-cyano-4,6-
d i subs t i tu ted pyr id ines .  M.  Bernard and co-worker171 repor ted the
anticonvulsant activity of 3-cyanopyridines. D. G. Bhatt et. al.172 have prepared
3-cyanopyridines as an immunosuppressive agent. U. Teu and co-worker173























































Hammana Abou and co-worker174 have studied anticancer and anti HIV
activity of 3-cyanopyridines. Abdallah Navine et. al.175 have prepared
cyanopyridine derivatives which showed analgesic and antiinflammatory activity.
Manna Fedele and co-worker176 have reported the antiinflammatory activity
of 3-cyanopyridines. H. Yoshida et. al.177 have studied the antihistamic and
antiallergic activity of 3-cyanopyridine derivatives. Abd El-Galil and co-
worker178 have prepared 3-cyanopyr id ines  ( IV)  and s tud ied the i r
pharmacological activity. Gadaginamath and co-worker179 have synthesised
various cyanopyridyl derivatives (V) and documented their variety of biological
activities.
J. A. Vann Allan et. al.180 have prepared fused heterocylic 3-cyanopyridine
(VI). Abu and co-worker181 have prepared novel fused cyanopyridines (VII)
for the treatment and preparation of systemic fungal infection.
S. V. Roman et. al.182 have synthesised 2-amino-3-cyanopyridines and
reported their biological activity. El-Taweel and co-worker183 have prepared































Parikh et. al.184 have synthesised 3-cyanopyridine derivatives as antimicrobial
agent.
Hussan M. & co-worker185 have prepared 3-cyanopyridines and reported
their pharmacological activity. Pyachenko U. D. and co-worker186 have
synthesised some cyanopyridines which are useful in the treatment of retroviral
disease.
Streightoff187 and Seydal188 have studied the bacteriostatic effect of some
substituted 3-cyanopyridines. Francis and co-worker189 have studied the effect
of some substituted pyridines on the growth of the walker carcinosarcome-256
in tissue culture. Barton et. al.190 have reported fungicidal and insecticidal
properties. W. Hoefling and co-worker191 have studied 3- and 4-cyanopyridines
as tuberculosis arresting agents.
K. Kadlec and Hanslian192 showed that 2-Methyl-3-nitro-4-methoxyethyl-
5-cyano-6-chloro pyridines caused occupational eczema in Vitamin B6 factory
workers. Rigterink and Raymond193 have studied the pesticidal activity of 3-
cyanopyridines. M. R. Pavia and co-worker194 have prepared N-substituted 2-
aminopyridines which possess anticonvulsant proper ty. 3-cyanopyridines
reported by L. Castedo et. al.195 showed a minimum inhibitory concentration
of 1.56 µg/ml against S. aureus.
W. Von Benbenburg and co-worker196 have synthesised 2-amino-3,6-
disubstituted pyridines as antiepileptic agents. V. Scott and E. Joseph197,198
have prepared 2-amino-3-cyanopyridine derivatives which were found to be
useful as antipsoriasis pharmaceuticals.
J .  J .  Ba ldwin199-201 have  prepared cyanopyr id ines  exh ib i t ing
antihyper tensive activity.
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CONTRIBUTION FROM OUR LABORATORY
A. R. Parikh, H. H. Parekh et. al. have synthesised cyanopyridines with
versatile biological activities202-209like anticancer and antitubarcular.
Moreover, Murtus et. al.210 synthesised 2-formyl pyridine thiosemicarbazone
as a carc inostat ic  agent .  Adr iano Afonso et .  a l .211 have found that
cyanopyridines are Fernesyl protein transferase inhibitors. Hussain et. al.212
have synthesised cyanopyridines as a antimicrobial agent. Wu Wenxue et. al.213
have synthesised cyanopyridines as histamine H3 antagonists. Saudi Manal N.
S. et. al.214 have found that cyanopyridines have fasciolicidal property. Harada
Hironori et. al.215 have prepared cyanopyridines and screened for their large
conductance calcium activated potassium channel opener activity.
Thus, diverse biological activities have been encountered in compounds
containing cyanopyridine ring system. To further assess the potential of such
type of compounds, study of cyanopyridines have been carried out as under.





SYNTHESIS AND BIOLOGICAL EVALUATION OF 1'N,3'-DIPHENYL-
4'-[2-AMINO-3-CYANO-6-ARYL-4-PYRIDYL] PYRAZOLES
In the past years, considerable evidence has been accumulated to
demonstrate the efficience of cyanopyridines. To further assess the potential of
such a class of compounds cyanopyridine derivatives of type (II) have been
synthesised by the condensation of malononitrile and ammonium acetate with
1-Aryl-3-[1'N,3'-diphenyl-4'-pyrazolyl]-2-propene-1-ones.
The constitution of the synthesised products have been characterised by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and mass spectrometry also. In mass spectrometry the m/z value
indicate the molecular weight, i.e. when R=2-Hydroxyphenyl, molecular
weight=429, m/z=428 (m-1) .
All the compounds have been also evaluated for their antibacterial activity
towards Gram positive and Gram negative bacterial strains and antifungal activity
towards Aspergillus niger at a concentration of 40µg/ml. The biological activity
of the synthesised compounds have been compared with standard drugs. Some
compounds have been found to have good and equivalent activity as compared
to the known antibiotics recorded on Page No. 53.















IR SPECTRAL STUDY OF 1 'N,3 ' -DIPHENYL-4 ' - [2 -AMINO-3-CYANO-
6-(p-FLUOROPHENYL)-4-PYRIDYL]-PYRAZOLE
I
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C-H str. (sym.) 2916 2975-2950 671
C–H str. (asym.) 2854 2962-2853 ''
C–H str. (asym.) 1446 1470-1435 ''
 Aromatic C-H str. 3058 3090-3030 "
C=C str. 1500 1500-1480 ''
C–H o.o.p.ben. 829 835-810 "
Pyrazole C=N str. 1589 1650-1600 673
moiety C-N str. 1226 1220-1020 "
Pyridine N-H str. (-NH2) 3355 3350-3250 "
ring C=N str. 2218 2240-2120 "
C=N str. 1531 1650-1600 "
C-F str. 759 800-750 "
Ether C-O-C str. (sym.) 1292 1275-1200 671













































PMR SPECTRAL STUDY OF 1 'N,3 ' -DIPHENYL-4 ' - [2 -AMINO-3-CYANO-
6-p-ANISYL-4-PYRIDYL]-PYRAZOLE
Internal Standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity Inference J Value
No. (δ ppm) of Protons In Hz
1 3.83 3H singlet Ar-OCH3 -
2 6.85 2H doublet CHcc' J=8.4
3 7.20 2H doublet CHdh -
4 7.35 2H multiplet CHeg -
5 7.50 6H multiplet CHa+CHj -
6 7.75 3H multiplet CHf+CHk -
7 7.82 2H doublet CHbb' J=8.4






















































































































































CH3 m/z = 326
+ +o
+
m/z = 428 (M - 1)
S B -  9
EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 1'N,3'-DIPHENYL-
4'-[2-AMINO-3-CYANO-6-ARYL-4-PYRIDYL] PYRAZOLES
[A] Synthesis of N-Phenylamino-α-methyl-phenyl azomethine
See [A] Part-I, Section-I (A).
[B] Synthesis of 1 N,3-Diphenyl-4-formyl pyrazole
See [A] Part-I, Section-I (B).
[C] Synthesis of 1-(p-Anisyl)-3-[1'N,3'-diphenyl-4'-pyrazolyl]-2-propene-
1-one
See [A] Part-I, Section-I (C).
[D] Synthesis of 1'N,3'-Diphenyl-4'-[2-amino-3-cyano-6-p-anisyl-
4-pyridyl]-pyrazole
A mixture of 1-(p-Anisyl)-3-[1'N,3'-diphenyl-4'-pyrazolyl]-2-propene-1-one
(3.8 g 0.01 M), malononitrile (0.66 g, 0.01 M) and ammonium acetate (6.61 g,
0.08 M) dissolved in methanol was refluxed for 12 hrs. The reaction product
was poured into ice, kept overnight, isolated and crystallized from ethanol.
Yield, 4.2g, (95%), m.p. 167
o
C. (C28H21N5O ; Requires : C,75.85; H, 4.74; N,
15.79; found : C,75.80; H, 4.70; N, 15.72%). TLC solvent system Acetone :
Benzene (2:8).
Similarly other cyanopyridines have been synthesised. The physical data
are recorded in Table No. 2
[E] Antimicrobial activity of 1'N,3'-Diphenyl-4'-[2-amino-3-cyano-6-
aryl-4-pyridyl]-pyrazoles
Antimicrobial testing was carried out as described in [A] Part-I, Section-I
























2a C6H5- C27H19N5 413 148 0.53 93 16.94 16.89
2b 4-Br-C6H4- C27H18N5Br 492 178 0.48 81 14.22 14.20
2c 4-Cl-C6H4- C27H18N5Cl 447.5 104 0.63 94 15.64 15.61
2d 4-F-C6H4- C27H18N5F 431 201 0.70 73 16.23 16.18
2e 4-CH3-C6H4- C28H21N5 427 103 0.44 78 16.38 16.40
2f 4-OCH3-C6H4- C28H21N5O 443 167 0.39 95 15.79 15.72
2g 2-OH-C6H4- C27H19N5O 429 210 0.49 85 16.31 16.33
2h 4-OH-C6H4- C27H19N5O 429 198 0.55 87 16.31 16.30
2i 4-NH2-C6H4- C27H20N6 428 186 0.65 97 16.61 19.58
2j 3-NO2-C6H4- C27H18N6O2 458 192 0.57 91 18.33 18.31
2k 4-NO2-C6H4- C27H18N6O2 458 230 0.70 86 18.33 18.30
2l 2-C4H3O- C25H17N5O 403 218 0.68 88 17.36 17.32
2m 2-C4H3S- C25H17N5S 419 178 0.63 92 16.69 16.67

































B.mega 17 16 12 16 20 16 18 14 18 11 15 22 17 23 22 24 25 0
s.aureus 11 20 17 13 11 13 12 17 17 14 19 11 12 22 23 17 24 0
E.coli 13 11 16 12 15 16 11 14 14 21 11 17 11 21 21 23 19 0
P.vulgaris 13 13 16 17 15 17 20 13 16 17 14 17 17 15 18 17 20 0
A.niger 16 11 17 12 18 16 23 14 12 17 11 21 14 0 0 0 0 25










COMPARATIVE STUDY OF ANTIMICROBIAL ACTIVITY WITH KNOWN ANTIBIOTICS
[A]
PART-II
Section - I : Antimicrobial activity of 1'N,3'-Diphenyl-4'-[2-amino-3-cyano-6-aryl-4-pyridyl]-pyrazoles
2e (20) 2b (20) 2j (21) 2g (20) 2g (23)
2l (22) 2k (19) 2l (17) 2l (21)
Ampicillin 23 22 21 15 -
Amoxicillin 22 23 21 18 -
Norfloxacin 24 17 23 17 -
Penicillin 25 24 19 20 -
Greseofulvin - - - - 25
B. mega S. aureus E. coli P. vulgaris A. niger
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity
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The chemistry of pyran with different functional group exhibit wide range
of applications in the field of pharmaceuticals, dyes, insecticides and sweet
smelling substances. Pyran ring system is also present in large number of natural
coloured compounds in Vitamin E, hemorrhagic compound in cloves, in fish
poisions, in certain alkaloids and other substances.
Pyran is a doubly unsaturated six membered ring system with a single
oxygen as hetero atom. The two double bonds may be conjugated as α or 1,2-
pyran or isolated as in γ or 1,4-pyran.
A degree of stabilisation of the pyran nucleus is achieved by substituting
phenyl group in the 2 or 4 and preferably also in the 6 position.
SYNTHETIC ASPECT
Various methods for the preparation of pyran derivatives have been cited
in the literature216-225.























The reaction of malononitrile with α,β-unsaturated system leads to the
formation of cyano 4H-pyran via Michael addition.
THERAPEUTIC IMPORTANCE
Literature survey revealed that various pyrans have resulted in many







7. CNS active agent237
8. Cytotoxic238
9. Inhibitors of cell proliferation239




































Moreover, Fathy F. Abdel-Latif et. al.245 have reported the synthesis of
2-amino-3-cyanopyran derivatives and studied their biological activity. Piao Minz,
Zhu et. al.246 have prepared biologically active 2-amino pyran derivatives.
Sharanin Y. U. A. et. al.247 have suggested new 2-amino-3-cyano-4H-
pyran derivatives (III).
Zwaagstra Mariel248 have newly synthesised pyran derivatives and tested
for antiashamatic activity. Boyer Frederick et. al.249 have prepared some new-
2-amino-3-cyano-4H-pyran and reported anti HIV agent and antiviral activity.
Some of the pyran derivatives have been patented for their use as
antihypertensive250, antiestogens251, antagonist252,253, antitumor254 and
antiviral255 activities. Synthesis and biological activity of pyran ring system
have been reported by O'Brien et. al.256.
Synthesis and anticancer activity of pyran (V) containing flourine have
been reported by Mohamed S. Abd et. al.257 4H-pyran of type (VI) were















El-Subbagh and co-worker258 have synthesised cyanopyran derivatives
and showed their antiviral activity. Corbou Romuld et. al.259 have synthesised
cyanopyran derivatives (VII) which have significant pharmacological activity.
CONTRIBUTION FROM OUR LABORATORY
Parikh A. R. et. al.260 have synthesised cyanopyrans bearing 2-chloro-6-
bromoquinoline nucleus as a potential antimicrobial and anticancer agents.
With a view to get better therapeutic agent, it was contemplated to
synthesise pyran derivatives to enhance the overall activity of resulting
compounds which have been described as under.





























SYNTHESIS AND BIOLOGICAL EVALUATION OF 1'N,3'-DIPHENYL-
4'-[2-AMINO-3-CYANO-6-ARYL-4-DIHYDROPYRANYL]-PYRAZOLES
3-Cyano-4,6-disubstituted 4H-pyrans are endowed with a variety of
pharmacodynamic act ivi t ies such as ant iconvulsant,  ant i inf lammatory,
antihypertensive, antitumor etc. Looking to the interesting proper ties of
cyanopyrans, it was considered worthwhile to synthesis some new 2-amino-3-
cyano-4H-pyrans bearing 1N,3-diphenyl pyrazole nucleus of type (III), for
obtaining biologically potent molecules by reacting chalcones of type (I) with
malononitrile as shown below.
The constitution of the synthesised products have been characterised by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and mass spectrometry also. In mass spectrometry the m/z value
indicate the molecular weight, i.e. when R=2-Furyl, molecular weight=406,
m/z=406 (m).
All the compounds have been also evaluated for their antibacterial activity
towards Gram positive and Gram negative bacterial strains and antifungal activity
towards Aspergillus niger at a concentration of 40µg/ml. The biological activity
of the synthesised compounds have been compared with standard drugs. Some
compounds have been found to have good and equivalent activity as compared












R = ArylType (III)
59
60
IR SPECTRAL STUDY OF 1 'N,3 ' -DIPHENYL-4 ' - [2 -AMINO-3-CYANO-
6-(p-FLUOROPHENYL)-4-DIHYDROPYRANYL]-PYRAZOLE
I
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C-H str. (sym.) 2916 2975-2950 675
C–H str. (asym.) 1448 1470-1435 "
Aromatic C-H str. 3060 3090-3030 671
C=C str. 1502 1520-1480 "
C-H o.o.p. (def.) 837 835-810 "
Pyrazole C=N str. 1596 1640-1590 673
moiety C-N str. 1232 1220-1020 "
Pyran N-H str. (-NH2) 3355 3350-3250 670
ring C=N str. 2216 2240-2120 "
C=N str. 1535 1650-1600 "
Fluorine C-F str. 759 800-750 671
Ether C-O-C str. (sym.) 1232 1275-1200 "








































PMR SPECTRAL STUDY OF 1'N,3'-DIPHENYL-4'-[2-AMINO-3-CYANO-6-p-TOLYL-
4-DIHYDROPYRANYL]-PYRAZOLE
Internal Standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity Inference J Value
No. (δ ppm) of Protons In Hz
1 2.30 3H singlet Ar-CH3 -
2 5.40 1H singlet CHl -
3 6.71-6.73 2H doublet CHoo' J=8.4
4 7.1-7.12 2H doublet CHnn' J=8.4
5 7.25 1H singlet CHm -
6 7.3-7.43 4H multiplet CHa,b,d,e -
7 7.47-7.52 2H triplet CHc,h -
8 7.75-7.79 4H multiplet CHf,g,i,j -















































































































































S B -  1 0
EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 1'N,3'-DIPHENYL-
4'-[2-AMINO-3-CYANO-6-ARYL-4-DIHYDROPYRANYL]-PYRAZOLES
[A] Synthesis of N-Phenylamino-α-methyl-phenyl azomethine
See [A] Part-I, Section-I (A).
[B] Synthesis of 1N,3-Diphenyl-4-formyl pyrazole
See [A] Part-I, Section-I (B).
[C] Synthesis of 1-(p-Anisyl)-3-[1'N,3'-diphenyl-4'-pyrazolyl]-2-propene-
1-one
See [A] Part-I, Section-I (C).
[D] Synthesis of 1'N,3'-Diphenyl-4'-[2-amino-3-cyano-6-p-anisyl-
4-dihydropyranyl]-pyrazole
A mixture of 1-(p-Anisyl)-3-[1'N,3'-diphenyl-4'-pyrazolyl]-2-propene-1-one
(3.8 g, 0.01 M), malononitrile (0.66 g, 0.01 M) dissolved in pyridine (20 ml) was
heated under reflux for 12 hrs. The product was isolated and crystallized from
absolute ethanol. Yield, 3.89g  (88%), m.p. 119oC.  (C28H22N4O ; Requires ;
C,78.14; H, 5.12; N, 13.01%; found : C,78.11; H,5.07; N,12.98%). TLC solvent
system Ethyl acetate : Hexane (3:7).
Similarly other cyanopyrans have been prepared. The physical constants
are recorded in Table No. 3.
[E] Antimicrobial activity of 1'N,3'-Diphenyl-4'-[2-amino-3-cyano-6-
aryl-4-dihydropyranyl]-pyrazoles
Antimicrobial activity was carried out as described in [A] Part-I, Section-I
























3a C6H5- C27H20N4O 416 114 0.46 78 13.45 13.41
3b 4-Br-C6H4- C27H19N4OBr 495 186 0.58 81 11.31 11.30
3c 4-Cl-C6H4- C27H19N4OCl 450.5 140 0.64 91 12.43 12.44
3d 4-F-C6H4- C27H19N4OF 434 210 0.71 92 12.90 12.93
3e 4-CH3-C6H4- C28H22N4O 430 119 0.63 88 13.01 12.98
3f 4-OCH3-C6H4- C28H22N4O2 446 208 0.60 80 12.55 12.53
3g 2-OH-C6H4- C27H20N4O2 432 218 0.56 85 12.96 12.94
3h 4-OH-C6H4- C27H20N4O2 432 148 0.49 82 12.96 12.97
3i 4-NH2-C6H4- C27H21N5O 431 98 0.61 80 16.23 16.21
3j 3-NO2-C6H4- C27H19N5O3 461 177 0.58 83 15.18 15.15
3k 4-NO2-C6H4- C27H19N5O3 461 213 0.50 90 15.18 15.19
3l 2-C4H3O- C25H18N4O2 406 220 0.63 90 13.78 13.79
3m 2-C4H3S- C25H18N4OS 422 190 0.43 81 13.26 13.27

































B.mega 14 15 12 16 13 22 16 12 11 12 23 13 15 23 22 24 25 0
s.aureus 13 11 12 17 19 16 11 18 20 13 14 12 16 22 23 17 24 0
E.coli 14 18 19 20 15 16 16 13 15 19 11 12 13 21 21 23 19 0
P.vulgaris 11 20 15 13 14 14 17 15 14 19 16 17 11 15 18 17 20 0
A.niger 17 11 12 24 18 11 12 14 13 12 11 22 14 0 0 0 0 25










COMPARATIVE STUDY OF ANTIMICROBIAL ACTIVITY WITH KNOWN ANTIBIOTICS
[A]
PART-III
Section - I : Antimicrobial activity of 1'N,3'-Diphenyl-4'-[2-amino-3-cyano-6-aryl-4-dihydropyranyl]-pyrazoles
3f (22) 3e (19) 3c (21) 3b (20) 3d (24)
3k (23) 3i (20) 3d (20) 3j (19) 3l (22)
3j (19)
Ampicillin 23 22 21 15 -
Amoxicillin 22 23 21 18 -
Norfloxacin 24 17 23 17 -
Penicillin 25 24 19 20 -
Greseofulvin - - - - 25
B. mega S. aureus E. coli P. vulgaris A. niger
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity
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Amongst nitrogen containing five membered heterocycles, pyrazolines
have proved to be the most useful frame work for biological activities, pyrazolines
have attracted attention of medicinal chemistry for both with regard to
heterocyclic chemistry and the pharmacological activities associated with them.
In 1967 Jarobe, reviewed the chemistry of pyrazolines, which have been studied
extensively for their biodynamic behaviour261 and industrial applications262.
SYNTHETIC ASPECT :
Different methods for the preparat ion of 2-pyrazol ine derivat ives
documented in literature are as follows.
1. 2-pyrazolines can be constructed by the cyclocondensation of chalcones
with hydrazine hydrate263.
2. 2-pyrazolines can also be prepared by the condensation of chalcone
dibromide with hydrazines264.
3. 2-pyrazolines can be synthesised by the cycloaddition of diazomethane to
substituted chalcone265.
4. Dipolar cycloaddition of nitrilimines of dimethyl fumarate, fumaronitrile














5. Epoxidation of chalcones have epoxy ketones which reacted with hydrazine
and phenyl hydrazine to give pyrazolines267.
Furthermore, B. Gyassi et. al.268 investigated the one pot synthesis of
some pyrazolines in dry media under microwave irradiation. S. Paul et. al.269
and Dandia Anshu et. al.270 have also described the microwave assisted
synthesis of 2-pyrazolines.
MECHANISM :
The following mechanism seems to be operable for the condensation of
chalcones with hydrazine hydrate271.
Nucleophilic attack by hydrazine at the β-carbon of the α,β-unsaturated
carbonyl system forms species (II), in which the -ve charge is mainly accomodated
by the electronegative oxygen atom.
Proton transfer from the nitrogen to -ve oxygen produces an intermediate
enol which simultaneously ketonises to ketoamine (III). Another intramolecular
nucleophilic attack by the primary amino group of ketoamine on its carbonyl











( i ) proton transfer



















carbonyl amine (IV). The later with a hydroxy group and amino group on the
same carbon lose water molecule to yield the pyrazolines.
THERAPEUTIC IMPORTANCE



















S. S. Sonarc et. al.292 have synthesised-3-(2-Acetoxy-4-methoxyphenyl)-
5-(substitutedphenyl)-pyrazolines (I) and tested their antimicrobial activity. H.
H. Parekh et. al.293 have also synthesised some new pyrazolines as an
antimicrobial agent.
Pyrazolines... 70
G. N. Mishirika et. al.294 have also prepared 2-pyrazolines of salicylic acid
(II) possessing antimicrobial properties.
Tuntawy Atif and co-worker295 have patented 3-methyl-4'-(substituted
phenylazo)-pyrazol-5-ones as antibacterial agent.
Moreover,  F.  Manna and co-worker296 have descr ibed 1-Acety l -
5-(2'-bromophenyl)-4,5-dihydro-3-(2'-hydroxyphenyl)-1H-pyrazolines (III) and
its derivatives which acts as potent antiinflammatory, analgesic and antipyratic
agents.
Udupi R. H. and Bhat A. R.297 have reported the synthesis and biological
activity of Mannich bases of cer tain 1,2-pyrazolines. Nugent Richard298






















Fuche Rainer et. al.299 have prepared some new 1H-pyrazoline (IV)
derivatives and reported them as pesticides.
Furthermore, Tsuboi et. al.300 have synthesised some new phenylcarbonyl
pyrazolines (V) as an insecticides and at 40% concentration shows 100%
mortality of spodopetra litura larve after seven drops.
Moreover, T. M. Stivenen et. al.301 have also investigated N-substituted
pyrazoline type insecticides. Tanka Katsohori302 have patented pyrazoline
derivatives as herbicides and Johannes et. al.303 as insecticides. Moritaz Z.
and Hadol304 to investigated a semi emperial molecular orbital study on the
reaction of aminopyrazolinyl azodye with singlet molecular oxygen.
Shivnanda M. K. and co-worker305 have prepared pyrazolines and reported
their antibacterial activity. E. Palska et. al.306 have prepared 3,5-diphenyl-2-




















R1 = H, Cl, Br, Me. MeO
R2 = H, Cl
(VI)
72
B. Shivarama Holla et. al.307,308 have synthesised pyrazolines as
antibacterial agent. Hiremath Sp. et. al.309 have synthesised pyrazolines as
analgesic, antiinflammatory and antimicrobial agent. Malhotra V. et. al.310 have
synthesised new pyrazolines as a cardiovascular agent (VII).
Almstead J. et. al.311 have prepared pyrazolines as vascularization agent.
Guniz Kucukguzel et. al.312 have synthesised pyrazolines as a antimicrobial
and anticonvulsant agents. Gulhan T. Z. and co-workers313 have prepared
pyrazolines as a hypotensive agent. Shalabh Sharma et. al.314 have synthesised
pyrazolines and tested their antiinflammatory activity (VIII).
Ashok Kumar et. al.315 have synthesised pyrazolines as anticonvulsant































CONTRIBUTION FROM OUR LABORATORY
Parekh et. al.317 have prepared 1-Acetyl-5-aryl-3-[3,-(3,4-dihydro-2-
methyl-4-one-3-quinazolinyl)-phenyl]-2-pyrazolines which possess antimicrobial
activity. Several pyrazolines bearing thymol moiety were evaluated for their
ability as potent antimicrobial by Hansa Parekh et. al.318 Parekh and co-
workers319 have prepared pyrazolines from arsanilic acid for their antimicrobial
activity. Parekh et. al.320,321 have synthesised and reported the antimicrobial
activity of pyrazolines. Parikh et. al.322 have synthesised some antimicrobial
pyrazolines. Parekh et. al.323 have synthesised phenyl pyrazolines bearing
quinoline (X) moiety and described their antimicrobial activity.

















(XI) R = Aryl, R1 = COCH3, Ph
Pyrazolines... 74
Recently, A. R. Parikh, H. H. Parekh and co-worker have synthesised newer
pyrazolines with variety of biological activity, described as under.
v 5-Aryl-1H-3-(6'-methoxy-β-naphthyl)-2-pyrazolines325.
v Preparation and antimicrobial326 activity of 3-[3'-(p-Chlorophenyl
sulphonamidophenyl)-5-aryl-1H/acetyl pyrazolines.
v Synthesis of some novel pyrazolines327 as biological potent agents.
v Antimicrobial activity of some newly synthesised pyrazolines328 derivatives.
v Pyrazolines329 as a antimicrobial agents.
v Antimicrobial activity of pyrazolines330.
In view of therapeutic activities shown by pyrazolines, it was contemplated
to synthesise some new pyrazolines in search of agents possessing higher
biological activity with least side effect have been described as under.
SECTION - I : SYNTHESIS AND BIOLOGICAL EVALUATION OF
3-ARYL-5- [1 'N,3 ' -DIPHENYL-4 ' -PYRAZOLYL] -
PYRAZOLINES
SECTION - II : SYNTHESIS AND BIOLOGICAL EVALUATION OF




SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-ARYL-5-[1'N,3'-
DIPHENYL-4'-PYRAZOLYL]-PYRAZOLINES
Pyrazolines are endowed with valid antimicrobial activites. Looking at their
versatile therapeutic importance and with an aim to getting better drug, it was
considered worthwhile to synthesise some new pyrazolines bearing 1N,3-diphenyl
pyrazole nucleus. The preparation of 3-Aryl-5-[1'N,3'-diphenyl-4'-pyrazolyl]-
pyrazolines (IV) have been undertaken by cyclocondensation of type (I) with
hydrazine hydrate.
The constitution of the synthesised products have been characterised using
elemental analysis, infrared and 1H nuclear magnetic resonance spectroscopy
and mass spectrometry also. In mass spectrometry the m/z value indicate the
mo lecu l a r  we i gh t ,  i . e .  when  R= p-Anisy l ,  mo l e cu l a r  we i gh t=394 ,
m/z=394 (m).
All the compounds have been also evaluated for their antibacterial activity
towards Gram positive and Gram negative bacterial strains and antifungal activity
towards Aspergillus niger at a concentration of 40µg/ml. The biological activity
of the synthesised compounds have been compared with standard drugs. Some
compounds have been found to have good and equivalent activity as compared










R = ArylType (IV)
76
Moreover, some selected compounds have been evaluated for their in vitro
biological assay towards a strain of Mycobacterium tuberculosis H37Rv at a
concentration of 6.25 µg/ml using Rifampin as a standard drug which have been
tested at Tuberculosis Antimicrobial Acquisition Co-ordinating Facility (TAACF),
Alabama, U. S. A.
77
78
IR SPECTRAL STUDY OF 3-(p-TOLYL)-5-[1'N,3'-DIPHENYL-4'-PYRAZOLYL]-
PYRAZOLINE
I
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C-H str. (sym.) 2922 2975-2950 670
C–H str. (asym.) 1446 1470-1435 "
C-H def. (asym.) 1353 1390-1350 "
Aromatic C-H str. 3064 3090-3030 671
C=C str. 1510 1585-1480 "
C-H i.p. def. 1002 1125-1000 "
C-H. o.o.p. def. 835 835-810 "
Pyrazole C=N str. 1598 1640-1600 673
moiety C-N str. 1172 1230-1020 "
Pyrazoline C-N str. 1112 1230-1020 672
ring N-H str. 3315 3320-3140 "
C=N str. 1548 1650-1550 "











































PMR SPECTRAL STUDY OF 3-(p-ANISYL)-5-[1'N,3'-DIPHENYL-4'-PYRAZOLYL]-
PYRAZOLINE
Internal Standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity Inference J Value
No. (δ ppm) of Protons In Hz
1 3.01-3.09 1H multiplet CHk
2 3.42-3.5 1H multiplet CHj
3 3.83 3H singlet Ar-OCH3
4 5.1-5.22 1H multiplet CHl
5 6.89-6.94 2H doublet CHcc' J=8.8
6 7.27-7.31 1H multiplet CHf
7 7.41-7.5 5H multiplet CHa
8 7.6-7.64 2H doublet CHbb' J=8.8
9 7.70-7.74 3H doublet CH d,e,g
10 7.8-7.88 1H multiplet CHh
























































































































m/z = 394 (M)
m/z = 272










S B -  2
EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-ARYL-5-[1'N,3'-
DIPHENYL-4'-PYRAZOLYL]-PYRAZOLINES
[A] Synthesis of N-Phenylamino-α-methyl-phenyl azomethine
See [A] Part-I, Section-I (A).
[B] Synthesis of 1N,3-Diphenyl-4-formyl pyrazole
See [A] Part-I, Section-I (B).
[C] Synthesis of 1-(p-Anisyl)-3-[1'N,3'-diphenyl-4'-pyrazolyl]-2-propene-
1-one
See [A] Part-I, Section-I (C).
[D] Synthesis of 3-(p-Anisyl)-5-[1'N,3'-diphenyl-4'-pyrazolyl]-pyrazoline
A mixture of 1-(p-Anisyl)-3-[1'N,3'-diphenyl-4'-pyrazolyl]-2-propene-1-one
(3.8 g, 0.01 M), hydrazine hydrate (2 g, 0.04 M) in 30 ml methanol was refluxed
for 12 hrs. The product obtained was filtered, washed with hot methanol and
crystallised from dioxan. Yield, 3.2 g (81%), m.p. 155oC. (C25H22N4O; Requires
: C, 76.14; H, 5.58; N, 14.20%; found : C, 76.10; H, 5.53; N, 14.17%). TLC
solvent system Acetone : Benzene (1:9).
Similarly other pyrazolines have been undertaken. The physical data are
recorded in Table No. 4.
[E] Antimicrobial activity of 3-Aryl-5-[1'N,3'-diphenyl-4'-pyrazolyl]-
pyrazolines
Antimicrobial testing was carried out as described in [A] Part - I, Section - I
(D). The zone of inhibition of the test solutions are reported in Graphical Chart
No. 4.
The antitubercular screening of the compounds of type (IV) was carried
out by TAACF, the Southern Research Institute, U.S.A. as described in
[A] Part - I, Section - I(E), and the percentage of inhibition data of the compounds






















4a C6H5- C24H20N4 364 140 0.72 70 15.37 15.36
4b 4-Br-C6H4- C24H19N4Br 443 198 0.57 73 12.64 12.60
4c 4-Cl-C6H4- C24H19N4Cl 398.5 198 0.63 80 14.05 14.03
4d 4-F-C6H4- C24H19N4F 382 86 0.66 85 14.65 14.61
4e 4-CH3-C6H4- C25H22N4 378 210 0.58 72 14.80 14.76
4f 4-OCH3-C6H4- C25H22N4O 394 155 0.54 81 14.20 14.17
4g 2-OH-C6H4- C24H20N4O 380 >230 0.43 77 14.73 14.69
4h 4-OH-C6H4- C24H20N4O 380 208 0.48 73 14.73 14.71
4i 4-NH2-C6H4- C24H21N5 379 148 0.59 90 18.46 18.43
4j 3-NO2-C6H4- C24H19N5O2 409 130 0.69 75 17.10 17.12
4k 4-NO2-C6H4- C24H19N5O2 409 166 0.49 69 17.10 17.13
4l 2-C4H3O- C22H18N4O 354 79 0.80 82 15.81 15.83
4m 2-C4H3S- C22H18N4S 370 97 0.57 80 15.12 15.10

































B.mega 11 20 14 16 11 21 12 18 13 22 17 15 13 23 22 24 25 0
s.aureus 12 18 11 22 20 13 19 23 15 16 12 11 13 22 23 17 24 0
E.coli 20 17 12 14 21 13 11 12 13 21 14 14 19 21 21 23 19 0
P.vulgaris 13 18 14 12 20 15 17 13 16 15 16 17 18 15 18 17 20 0
A.niger 15 17 19 21 11 13 14 16 18 20 23 18 15 0 0 0 0 25










COMPARATIVE STUDY OF ANTIMICROBIAL ACTIVITY WITH KNOWN ANTIBIOTICS
[A]
PART-IV
Section - I : Antimicrobial activity of 3-Aryl-5-[1'N,3'-diphenyl-4'-pyrazolyl]-pyrazolines
4b (20) 4d (22) 4a (20) 4e (20) 4d (21)
4f (21) 4e (20) 4e (21) 4b (18) 4j (20)
4j (22) 4h (23) 4j (21) 4m (18) 4k (23)
Ampicillin 23 22 21 15 -
Amoxicillin 22 23 21 18 -
Norfloxacin 24 17 23 17 -
Penicillin 25 24 19 20 -
Greseofulvin - - - - 25
B. mega S. aureus E. coli P. vulgaris A. niger
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity
Zone of inhibition in m.m.
8
5
TABLE NO. 4a: DATA OF IN VITRO EVALUATION OF ANTITUBERCULAR ACTIVITY
TAACF, Southern Research Institute Dr. A. R. Parikh
Primary Assay Summary Report Saurashtra University
Sample Corp Where,R= Supplier Assay MTb MIC % comment
ID ID Strain µg/ml Inhib
162358 SHI-30 4-F-C6H4- Sau.uni Alamar H37Rv >6.25 57
162361 SHI-33 2-OH-C6H4- Sau.uni Alamar H37Rv >6.25 56  ''
162356 SHI-28 4-Br-C6H4- Sau.uni Alamar H37Rv >6.25 53  ''
162367 SHI-39 2-C4H3S Sau. uni. Alamar H37Rv >6.25 53 "
162362 SHI-34 4-OH-C6H4- Sau.uni Alamar H37Rv >6.25 45  ''
162363 SHI-35 4-NH2-C6H4- Sau.uni Alamar H37Rv >6.25 40  ''
162355 SHI-27 C6H5- Sau.uni Alamar H37Rv >6.25 39
162364 SHI-36 3-NO2-C6H4- Sau.uni Alamar H37Rv >6.25 39  ''
162365 SHI-37 4-NO2-C6H4- Sau.uni Alamar H37Rv >6.25 35  ''
162360 SHI-32 4-OCH3-C6H4- Sau.uni Alamar H37Rv >6.25 33  ''
162359 SHI-31 4-CH3-C6H4- Sau.uni Alamar H37Rv >6.25 32  ''
162366 SHI-38 2-C4H3O- Sau.uni Alamar H37Rv >6.25 23  ''
162357 SHI-29 4-Cl-C6H4- Sau.uni Alamar H37Rv >6.25 16  ''
NIAID/ Southern Research institute/ GWL Hansen's Center/
Colorado state university proprietary information.
MIC Ri fampin
= 0.025mg/ml








SYNTHESIS AND BIOLOGICAL EVALUATION OF 1N-PHENYL-3-ARYL-
5-[1'N,3'-DIPHENYL-4'-PYRAZOLYL]-PYRAZOLINES
Looking to the interesting therapeutic activities of pyrazolines, it was
considered worthwhile to synthesise compounds bearing 1N,3-diphenyl pyrazole
moiety linked to the pyrazoline nucleus. Pyrazolyl pyrazoline of type (V) have
been prepared by the action of 1-Aryl-3-(1'N,3'-diphenyl-4'-pyrazolyl)-2-propene-
1-ones with phenylhydrazine in presence of piperidine.
The constitution of the synthesised products have been characterised using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy
and mass spectrometry also. In mass spectrometry the m/z value indicate the
molecular weight, i.e. when R=4-methoxyphenyl, molecular weight=470,
m/z=470 (m).
All the compounds have been also evaluated for their antibacterial activity
towards Gram positive and Gram negative bacterial strains and antifungal activity
towards Aspergillus niger at a concentration of 40µg/ml. The biological activity
of the compounds have been found to have good and equivalent activity as














IR SPECTRAL STUDY OF 1N-PHENYL-3-(p-ANISYL)-5-[1 'N,3 ' -DIPHENYL-
4'-PYRAZOLYL]-PYRAZOLINE
I
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C-H str. (sym.) 2922 2975-2950 670
C–H str. (asym.) 1444 1470-1435 "
C-H str. (sym.) 1353 1390-1350 "
Aromatic C-H str. 3064 3090-3030 671
C=C str. 1510 1585-1480 "
C-H i.p. def. 1002 1125-1000 "
C-H. o.o.p. def. 835 835-810 "
Pyrazole C=N 1598 1640-1600 673
moiety C-N 1174 1230-1020 "
Pyrazoline C-N str. 1109 1230-1020 673
ring C=N str. 1548 1650-1550 "






















































PMR SPECTRAL STUDY OF 1N-PHENYL-3-(p-ANISYL)-5-[1'N,3'-DIPHENYL-
4'-PYRAZOLYL]-PYRAZOLINE
Internal Standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity Inference J Value
No. (δ ppm) of Protons In Hz
1 3.17-3.25 1H quartet CHl -
2 3.77-3.87 1H triplet CHr -
3 3.83 3H singlet Ar-OCH3 -
4 5.44-5.50 1H quartet CHp -
5 6.76-6.81 1H triplet CHb -
6 6.89-6.92 2H doublet CHdd' J=8.7
7 7.0-7.1 2H doublet CHfh -
8 7.16-7.25 3H multiplet CHe,g,i -
9 7.34-7.4 2H triplet CHk,m -
10 7.42-7.45 1H doublet CHl -
11 7.49-7.54 2H triplet CH j,n -
12 7.62-7.68 4H triplet CHa -



























































































































































SYNTHESIS AND BIOLOGICAL EVALUATION OF 1N-PHENYL-3-ARYL-
5-[1'N,3'-DIPHENYL-4'-PYRAZOLYL]-PYRAZOLINES
[A] Synthesis of N-Phenylamino-α-methyl-phenyl azomethine
See [A] Part-I, Section-I (A).
[B] Synthesis of 1N,3-Diphenyl-4-formyl pyrazole
See [A] Part-I, Section-I (B).
[C] Synthesis of 1-(p-Anisyl)-3-[1'N,3'-diphenyl-4'-pyrazolyl]-2-propene-
1-one
See [A] Part-I, Section-I (C).
[D] Synthesis of 1N-phenyl-3-(p-Anisyl)-5-[1'N,3'-diphenyl-4'-pyrazolyl]-
pyrazoline
A mixture of 1-(p-Anisyl)-3-[1'N,3'-diphenyl-4'-pyrazolyl]-2-propene-1-one
(3.8 g, 0.01 M), phenylhydrazine (1.08 g, 0.01 M) in 25 ml methanol was reflux
for 12 hrs. in presence of basic catalyst piperidine. The reaction product was
poured into ice, crude product was isolated, crystal l ized from dioxan.
Yield, 3.8 g (81%), m.p. 176oC. (C31H26N4O; Requires : C, 79.15; H, 5.53;
N, 11.91%; found : C, 79.10; H, 5.48; N, 11.88%). TLC solvent system Acetone
: Benzene (2:8).
Similarly other pyrazolines were prepared. The physical data are recorded
in Table No. 5.
[E] Antimicrobial activity of 1N-Phenyl-3-aryl-5-[1'N,3'-diphenyl-4'-
pyrazolyl]-pyrazolines
Antimicrobial testing was carried out as described in [A] Part - I, Section -
























5a C6H5- C30H24N4 440 156 0.70 76 12.72 12.70
5b 4-Br-C6H4- C30H23N4Br 519 146 0.63 80 10.79 10.77
5c 4-Cl-C6H4- C30H23N4Cl 474.5 124 0.59 81 11.80 11.77
5d 4-F-C6H4- C30H23N4F 458 218 0.53 70 12.22 12.20
5e 4-CH3-C6H4- C31H26N4 454 115 0.49 77 12.33 12.30
5f 4-OCH3-C6H4- C31H26N4O 470 176 0.53 81 11.91 11.88
5g 2-OH-C6H4- C30H24N4O 456 193 0.57 84 12.27 12.29
5h 4-OH-C6H4- C30H24N4O 456 208 0.65 78 12.27 12.28
5i 4-NH2-C6H4- C30H25N5 455 217 0.69 82 15.37 15.33
5j 3-NO2-C6H4- C30H23N5O2 485 196 0.49 79 14.42 14.40
5k 4-NO2-C6H4- C30H23N5O2 485 179 0.59 79 14.42 14.43
5l 2-C4H3O- C28H22N4O 430 110 0.68 80 13.01 13.03
5m 2-C4H3S- C28H22N4S 446 124 0.63 81 12.55 12.53
*TLC Solvent System : 5a, 5b, 5e, 5f, 5i, 5j, 5k Acetone : Benzene (2 : 8).

































B.mega 17 13 17 20 14 15 12 15 12 17 12 22 18 23 22 24 25 0
s.aureus 20 18 12 21 14 19 13 11 16 19 14 17 13 22 23 17 24 0
E.coli 15 20 19 20 14 18 14 19 21 16 11 11 13 21 21 23 19 0
P.vulgaris 11 16 19 12 18 20 19 15 11 13 19 12 12 15 18 17 20 0
A.niger 18 16 17 22 17 13 18 23 15 19 14 23 14 0 0 0 0 25










COMPARATIVE STUDY OF ANTIMICROBIAL ACTIVITY WITH KNOWN ANTIBIOTICS
[A]
PART-IV
Section - II : Antimicrobial activity of 1N-Phenyl-3-aryl-5-[1'N,3'-diphenyl-4'-pyrazolyl]-pyrazolines
5d (20) 5a (20) 5b (20) 5c (19) 5d (22)
5l (22) 5d (21) 5d (20) 5f (20) 5h (23)
5f (19) 5i (21) 5g (19) 5l (23)
5j (19)
Ampicillin 23 22 21 15 -
Amoxicillin 22 23 21 18 -
Norfloxacin 24 17 23 17 -
Penicillin 25 24 19 20 -
Greseofulvin - - - - 25
B. mega S. aureus E. coli P. vulgaris A. niger
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity
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Pyrimidine derivatives occur in natural products331 like nucleic acids and
Vitamin - B have remarkable pharmaceutical impor tance becuse of their
biological activities332-336. Several analogs of nucleic acids have been used as
compounds that interfere with the synthesis and functioning of nucleic acids,
and example is fluorouracil which has been used in cancer treatment. Pyrimidines
are among those molecules that make life possible as being same of the building
blocks of DNA and RNA.
Some pyrimidines of physiological ly as wel l  as pharmacological ly
importance are as under: e.g. cytosine, beclmethrin (I), blasticidin (II).
Synthetic pyrimidinone derivatives contribute much to the searchable
literature of pyrimidinone derivatives, in huge libraries owing to their wide
applicability in different fields.
SYNTHETIC ASPECT
Different methods for the synthesis of pyrimidinones have been cited in
the literature337.





















The reaction of α,β-unsaturated system with urea leds to the formation of


































































Pyrimidinone derivatives have proven to be of great impor tance in
exhibiting and enhancing the biological activities such as,
1. Antitumor339
2. Carcinostatic340










Moreover, Azaryan et. al.363 have synthesised pyrimidine diones as
antitumor agent. Krivongov and co-worker364 have synthesised pyrimidinone
derivatives possessing immunotropic and antiinflammatory activity. Omer M. T.
and co-worker365 have prepared some new pyrimidinone derivatives showed
moderate activity against the growth of Bacillus subtilis, Staphylococus
aureus and Aspergillus niger. Amuti Kofies et. al.366 have suggested that

















K. Mogilaiah367 have prepared spiropyrimidinones as antibacterial. Drewes
and Wilhelm368 have synthesised pyrimidinones as herbicidal agents.
Timothy and co-worker369 have suggested imidazolyl pyrimidinones as
antiviral. Nagamatsu et. al.370 have prepared some new triazolo [3,4-c]
pyrimidinone as Xanthin oxidase inhibitors. Andree Roland et. al.371 have
prepared oxazolyl uracil as herbicidal and insecticidal. Yari M. M. and co-
worker372 have investigated the pyrimidinone derivatives which possess calcium
antagonist activity.
Bruce M. A. and co-worker373 prepared the dihydropyrimidinones (VII)
as NPY antagonists.
Sidler and Larsen374 have reported pyrimidinone derivatives (VIII), useful








R = Alkyl,  R1 = Alkyl

































Mona Mahram and co-worker375 have synthesied pyrimidine derivatives
as potent antimicrobial and antitumor agents.
Saxena A. K.  and co-worker376 have prepared 2,6-disubst i tuted
pyrimidinones as CNS agent (IX).
Pyrimidinone derivatives377,378 have found to be calcium channel blocker
(X) .  Barbul iene M.  M.  e t .  a l .379 have synthes ised pyr imidinones as
antiinflammatory agent.
Recently, Amjad Ali et. al.380 have synthesised new fused pyrimidinones
as antimicrobial agents. Abd El-Galil et. al.381 have synthesised pyrimidinone
as androgenic anabolic and antiinflammatory agents. Martin Bolli et. al.382
have synthesised pyrimidines as endothelin receptor antagonists. Patricia F. F.
et. al.383 have synthesised and screened for their leukocyte functions inhibitor
activity. Dumas Jacques et. al.384 have synthesised pyrimidinones and tested
their hyderproliferative disorder activity. Adenosine receptor antagonists
























Thus, diverse biological activities have been encountered in compounds
containing pyrimidinone ring system. To further assess the potential of such
type of compounds, study of pyrimidinones have been carried out as under.
SECTION - I : SYNTHESIS AND BIOLOGICAL EVALUATION OF
6-ARYL-4-[1'N,3'-DIPHENYL-4'-PYRAZOLYL]-1,2,3,4-
TETRAHYDROPYRIMIDIN-2-ONES
SECTION - II : SYNTHESIS AND BIOLOGICAL EVALUATION OF





SYNTHESIS AND BIOLOGICAL EVALUATION OF 6-ARYL-4-[1'N,3'-
DIPHENYL-4'-PYRAZOLYL]-1,2,3,4-TETRAHYDROPYRIMIDIN-2-ONES
Looking to the interesting pharmacological and agricultural activity of
pyrimidinone ring system, It was considered worthwile to synthesis compounds
bearing 1N,3-diphenyl-pyrazole nucleus linked to the pyrimidinone nucleus.
Pyrimidinone of type (VI) have been prepared by the condensation of 1-Aryl-
3-[1'N,3'-diphenyl-4'-pyrazolyl]-2-propene-1-one with urea in presence of
catalytic amount of conc. HCl as shown under.
The constitution of the synthesised products have been characterised by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and mass spectrometry also. In mass spectrometry the m/z value
indicate the molecular weight, i.e. when R=p-Tolyl, molecular weight=406,
m/z=405 (m-1).
All the compounds have been also evaluated for their antibacterial activity
towards Gram positive and Gram negative bacterial strains and antifungal activity
towards Aspergillus niger at a concentration of 40µg/ml. The biological activity
of the synthesised compounds have been compored with standerd drugs. Some
compounds have been found to have good and equivalent activity as compared


















IR SPECTRAL STUDY OF 6-(p-TOLYL)-4-[1'N,3'-DIPHENYL-4'-PYRAZOLYL]-1,2,3,4-
TETRAHYDROPYRIMIDIN-2-ONE
I
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C-H str. (sym.) 2852 2880-2860 670
C-H str. (asym.) 1448 1470-1435 "
C-H def. (sym.) 1355 1390-1350 "
Aromatic C-H str. 3066 3090-3030 671
C=C str. 1502 1520-1480 "
1110 1125-1090 "
C-H i.p.def. 1026 1070-1000 "
Pyrazole C=N str. 1596 1640-1600 673
moiety C-N str. 1234 1230-1020 "
Pyrimidinone N-H str. 3244 3220-3140 672










































PMR SPECTRAL STUDY OF 6-(p-TOLYL)-4-[1'N,3'-DIPHENYL-4'-PYRAZOLYL]-1,2,3,4-
TETRAHYDROPYRIMIDIN-2-ONE
Internal Standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity Inference J Value
No. (δ ppm) of Protons In Hz
1 2.38 3H singlet Ar-CH3
2 6.58 1H singlet CHk
3 7.22-7.29 3H multiplet CHcc' + CHj J=8.5
4 7.34-7.39 2H triplet CH d,h
5 7.48-7.58 7H multiplet CHa+CH e,g
6 7.66-7.70 2H multiplet CH i,f
7 7.88-7.71 2H doublet CH bb' J=8.5
















































































































m/z = 406 (M - 1)







m/z = 258m/z = 233




















S B -  7
EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 6-ARYL-4-[1'N,3'-
DIPHENYL-4'-PYRAZOLYL]-1,2,3,4-TETRAHYDROPYRIMIDIN-2-ONES
[A] Synthesis of N-Phenylamino-α-methyl-phenyl azomethine
See [A] Part-I, Section-I (A).
[B] Synthesis of 1N,3-Diphenyl-4-formyl pyrazole
See [A] Part-I, Section-I (B).
[C] Synthesis of 1-(p-Tolyl)-3-[1'N,3'-diphenyl-4'-pyrazolyl]-2-propene-
1-one
See [A] Part-I, Section-I (C).
[D] Synthesis of 6-(p-Tolyl)-4-[1'N,3'-diphenyl-4'-pyrazolyl]-1,2,3,4-
tetrahydropyrimidin-2-one
A mixture of 1-p-Tolyl-3-(1'N,3'-diphenyl-4'-pyrazolyl)-2-propene-1-one
(3.64 g, 0.01 M) and urea (0.60 g, 0.01 M) was refluxed at 90oC for 14 hrs in
presence of acid catalyst like HCl in methanol. The reaction product was poured
into ice, crude product was isolated, crystallized from dioxan. Yield, 2.7 g (66%),
m.p. 188oC. (C26H22N4O; Requires : C, 76.85, H, 5.42; N, 13.78%; found : C,
76.81; H, 5.38; N, 13.72%). TLC solvent system Acetone : Benzene (2:8).
Similarly other pyrimidinones were prepared. The physical data are
recorded in Table No. 6.
[E] Antimicrobial activity of 6-Aryl-4-[1'N,3'-diphenyl-4'-pyrazolyl]-
1,2,3,4-tetrahdropyrimidin-2-ones
Antimicrobial testing was carried out as described in [A] Part-I, Section-I
























6a C6H5- C25H20N4O 392 110 0.68 70 14.28 14.27
6b 4-Br-C6H4- C25H19N4OBr 471 193 0.57 68 11.89 11.83
6c 4-Cl-C6H4- C25H19N4OCl 426.5 211 0.71 58 13.12 13.10
6d 4-F-C6H4- C25H19N4OF 410 217 0.69 71 13.65 13.60
6e 4-CH3-C6H4- C26H22N4O 406 188 0.52 66 13.78 13.72
6f 4-OCH3-C6H4- C26H22N4O2 422 186 0.55 61 13.26 13.23
6g 2-OH-C6H4- C25H20N4O 408 221 0.63 72 13.72 13.76
6h 4-OH-C6H4- C25H20N4O 408 208 0.71 67 13.72 13.70
6i 4-NH2-C6H4- C25H21N5O 407 189 0.49 60 17.19 17.18
6j 3-NO2-C6H4- C25H19N5O3 437 168 0.62 73 16.01 16.00
6k 4-NO2-C6H4- C25H19N5O3 437 196 0.73 65 16.01 15.99
6l 2-C4H3O- C23H18N4O2 382 194 0.55 66 14.65 14.62
6m 2-C4H3S- C23H18N4OS 398 115 0.58 74 14.06 14.02
*TLC Solvent System : 6a-6d, 6i-6k  : Acetone : Benzene (2 : 8).


































B.mega 22 16 17 13 13 23 17 11 18 17 11 12 18 23 22 24 25 0
s.aureus 17 18 17 19 16 17 17 17 16 20 17 13 22 22 23 17 24 0
E.coli 17 20 18 14 19 20 13 20 12 11 20 18 17 21 21 23 19 0
P.vulgaris 18 15 19 15 16 18 18 15 19 20 12 11 19 15 18 17 20 0
A.niger 18 17 22 13 12 22 14 16 23 17 15 24 13 0 0 0 0 25











COMPARATIVE STUDY OF ANTIMICROBIAL ACTIVITY WITH KNOWN ANTIBIOTICS
[A]
PART-V
Section - I : Antimicrobial activity of 6-Aryl-4-[1'N,3'-diphenyl-4'-pyrazolyl]-1,2,3,4-tetrahydropyrimidin-2-ones
6a (22) 6j (20) 6b (20) 6c (19) 6i (23)
6f (23) 6m (22) 6f (20) 6i (19) 6l (24)
6h (20) 6j (20)
6k (20)
Ampicillin 23 22 21 15 -
Amoxicillin 22 23 21 18 -
Norfloxacin 24 17 23 17 -
Penicillin 25 24 19 20 -
Greseofulvin - - - - 25
B. mega S. aureus E. coli P. vulgaris A. niger
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity





SYNTHESIS AND BIOLOGICAL EVALUATION OF 5-ALKYL-6-ALKYL/
ARYL-4-(1'N,3'-DIPHENYL-4'-PYRAZOLYL)-1,2,3,4-TETRAHYDRO
PYRIMIDIN-2-ONES
With a view to synthesising the compounds having better therapeutic activity
the pyrimidinones of type (VII) have been prepared by the condensation of
1N,3-diphenyl-4-formyl pyrazole, urea and different 1,3-diketones in presence
of HCl as catalyst as given  below.
The constitution of synthesised products have been characterised by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy
and mass spectrometry also. In mass spectrometry the m/z value indicate the
molecu lar  weight ,  i .e .  when R1=Carbethoxy,  R2=methy l ,  molecu lar
weight=402, m/z=403 (m+1).
All the compounds have been also evaluated for their antibacterial activity
towards Gram positive and Gram negative bacterial strains and antifungal activity
towards Aspergillus niger at a concentration of 40µg/ml. The biological activity
of the synthesised compounds have been compared with standard drugs. Some
compounds have been found to have good and equivalent activity as compared























IR SPECTRAL STUDY OF 6-METHYL-5-CARBMETHOXY-4-[1'N,3'-DIPHENYL-
4'-PYRAZOLYL]-1,2,3,4-TETRAHYDROPYRIMIDIN-2-ONE
I
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C-H str. (sym.) 2950 2975-2950 670
C-H str. (asym.) 1452 1470-1435 "
C-H def. (sym.) 1379 1390-1350 "
Aromatic C-H str. 3057 3090-3030 673
C=C str. 1500 1585-1480 "
C-H i.p. def. 1099 1125-1000 "
C-H o.o.p. def. 804 835-810 "
Pyrazole C=N str. 1598 1640-1600 672
moiety C-N str. 1213 1230-1020 "
Pyrimidinone N-H str. 3361 3320-3140 670
ring Ring C=O str. 1641 1690-1630 "
Ester C=O str. 1695 1745-1680 "
Ether C-O-C str (sym.) 1234 1275-1200 "






















































PMR SPECTRAL STUDY OF 5-CARBETHOXY-6-METHYL-4-[1'N,3'-DIPHENYL-
4'-PYRAZOLYL]-1,2,3,4-TETRAHYDROPYRIMIDIN-2-ONE
Internal Standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity Inference
No. (δ ppm) of Protons
1 1.19-1.25 3H triplet -CHg
2 2.32 3H singlet -CHe
3 4.13-4.25 2H multiplet -CHf
4 5.88 1H singlet CHd
5 7.25-7.65 10H multiplet CH a,b
6 8.23 1H singlet CHc























































































































































































S B -  8
EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 5-ALKYL-6-ALKYL/
ARYL-4-[1'N,3'-DIPHENYL-4'-PYRAZOLYL]-1,2,3,4-TETRAHYDRO
PYRIMIDIN-2-ONES
[A] Synthesis of N-Phenylamino-α-methyl-phenyl azomethine
See [A] Part-I, Section-I (A).
[B] Synthesis of 1N,3-Diphenyl-4-formyl pyrazole
See [A] Part-I, Section-I (B).
[C] Synthesis of 5-Carbethoxy-6-methyl-4-[1'N,3'-diphenyl-4'-pyrazolyl]-
1,2,3,4-tetrahydropyrimidin-2-one
A mixture of 1N,3-Diphenyl-4-formyl-pyrazole (2.48 g, 0.01 M), ethyl aceto
acetate (1.3 g, 0.01 M) and urea (0.60 g, 0.01 M) was refluxed for 12 hrs. in
presence of acid catalyst like HCl in methanol. The reaction product was poured
into ice, crude product was isolated and crystallized from DMF. Yield, 2.95 g
(73%), m.p. 160oC. (C23H22O3N4; Requires : C, 68.87; H, 5.47; N, 13.92%;
found : C, 68.84; H, 5.42; N, 13.89%). TLC solvent system Acetone : Benzene
(3:7).
Similarly other pyrimidinones have been prepared. The physical data are
recorded in Table No. 7.
[D] Antimicrobial activity of 5-Alkyl-6-alkyl/aryl-4-[1'N,3'-diphenyl-4'-
pyrazolyl]-1,2,3,4-tetrahydropyrimidin-2-ones
Antimicrobial testing was carried out as described in [A] Part-I, Section-I










7a -COCH3 -CH3 C22H20O2N4 372 178 0.56 80 15.05 15.01
7b -COOC2H5 -NH2 C22H21O3N5 403 195 0.65 81 17.36 17.33
7c -COOCH3 -CH3 C22H20O3N4 388 195 0.70 76 14.42 14.39
7d -COOC2H5 -CH3 C23H22O3N4 402 160 0.57 73 13.92 13.89
7e -CN -NH2 C20H16ON6 356 178 0.50 70 23.60 23.62
7f -COOC2H5 C6H5- C28H24O3N4
464 123 0.68 81 12.06 12.03
7g -COOC2H5 4-Br-C6N4- C28H23O3N4Br 543 193 0.58 68 10.31 10.34
7h -COOC2H5 4-Cl-C6H4- C28H23O3N4Cl 498.5 211 0.70 74 11.23 11.25
7i -COOC2H5 4-F-C6H4- C28H23O3N4F 482 179 0.49 60 11.61 11.60
7j -COOC2H5 4-CH3-C6H4- C29H26O3N4 478 223 0.59 63 11.71 11.69
7k -COOC2H5 4-OCH3-C6H4- C29H26O4N4 494 115 0.66 65 11.33 11.30
7l -COOC2H5 2-OH-C6H4- C28H26O4N4 480 79 0.58 75 11.66 11.65
7m -COOC2H5 4-OH-C6H4
- C28H26O4N4 480 210 0.60 68 11.66 11.68
*TLC Solvent System : 7a-7f : Acetone : Benzene (3 : 7).

























GRAPHICAL CHART NO. 7 :      ANTIMICROBIAL ACTIVITY OF  5-ALKYL- 6-ALKYL/ARYL-4-[1’N,3’-DIPHENYL-






















B.mega 17 20 16 15 21 18 11 16 12 17 13 18 14 19 23 22 24 25 0
s.aureus 18 17 22 18 20 16 20 11 17 12 16 13 13 14 22 23 17 24 0
E.coli 22 19 22 17 21 18 14 15 18 14 19 12 18 17 21 21 23 19 0
P.vulgaris 17 21 18 20 18 19 15 13 16 11 17 15 18 16 15 18 17 20 0
A.niger 19 17 23 18 24 16 19 15 20 20 11 13 12 20 0 0 0 0 25











COMPARATIVE STUDY OF ANTIMICROBIAL ACTIVITY WITH KNOWN ANTIBIOTICS
[A]
PART-V
Sect ion -  I I  :  Ant imicrobia l  act iv i ty  o f  5 -Alkyl -6 -a lky l /ar y l -4 - [1 'N,3 ' -d iphenyl -4 ' -pyrazoly l ] -
1,2,3,4-tetrahydropyrimidin-2-ones
7b (20) 7c (22) 7a (22) 7b (21) 7c (23)
7e (21) 7e (20) 7c (22) 7d (20) 7e (24)
7g (20) 7e (21) 7f (19)
Ampicillin 23 22 21 15 -
Amoxicillin 22 23 21 18 -
Norfloxacin 24 17 23 17 -
Penicillin 25 24 19 20 -
Greseofulvin - - - - 25
B. mega S. aureus E. coli P. vulgaris A. niger
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity
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Barbitones, which belongs to an important group of nitrogen containing
heterocyclic compounds have been extensively explored for their application in
the field of medicine. Most important is the effect of barbiturates on CNS.
Barbituric aicd derivatives constitute an important class of compounds possessing
diverse type of biological properties including hyphotic, sedative, anticonvulsant,
cardiovascular etc.
Barbituric acid usually represented as the trione (I, R1=R2=H) was first
made about 1864 and it has no hypnotic properties. The origin of the name is
lost, although there are several plausible explanations associated with St.
Barbara's feast day, a favourite Munchen Kellnerin rejoicing in that given name,
and even the barba which is a beard of the business end of a key.
SYNTHETIC ASPECT
Dif ferent  methods are used for  the preparat ion of  barbi tones in
literature386,387
1. Cao-Yan Weu et. al.388 have prepared barbitones by reaction of different











2. M. R. Mahmoud et. al.389 have synthesised barbituric acid derivatives
from chalcone.
3. Ogus Funda et. al.390 have prepared barbitones by the reaction of acetone
and barbituric aicd.
THERAPEUTIC IMPORTANCE
The first hyphotic barbiturate, 5,5-diethyl barbituric acid (barbital, Veronal
; I; R1R2=Et) was made in 1904, was introduced into medicine in 1905, and is
s t i l l  used somet imes;  the second was 5-ethyl -5-phenylbarbi tur ic  ac id
(phenobarbital, Luminal, I; R1=Et, R2=Ph), also prepared in 1904 but used as
a long acting CNS depressant only from 1912 until the present day. Several
thousand active barbiturates were made subsequently but scarcely a dozen are
still used to any extent. Among these are pentobarbital (Nembutal; I; R1=C2H5,
R2=CHMePr), amobarbital (Amytal ; I; R1=C2H5
, R2=CH2CH2CHMe2),
secobarbital (Seconal; I; R1=CH2 CH=CH2, R
2=CHMePr), hexobarbital




























The 'pseudo-barbi turate ' ,  2-methyl-3-o- to ly lquinazol in-4(3H)-one
(methaqualone, Revonal; IV) has an ever winder spectrum of activities that do
the barbiturates proper; it appears to be quite widely used as a sedative, hyphotic,
anticonvulsant, antispasmodic and local anaesthetic agent394.
Some barbituric acid derivatives used as sedative and hyphotic is
carbubarb395, which is used as veternary anaesthetics. Some isoxazolo
pyrimidines have been studied because of their potential as pesticidal396,397
activity. Some barbiturates showing cardiovascular398-400 and analgesics and
antiinflammatory activities401 have been reported.
Ulf Wellmar et. al.402 have synthesised some uracil derivatives and
screened for antiviral activity403,404. Raymond et. al.405 have synthesised
some barbiturates (V), which showed anticancer activity. Mahmoud et. al.406































Some isoxazolopyrimidines have been extensively studied and reported as
antagonist407 and antitumor408 activity. Wolf-Gang et. al.409 have reported
5-(3-Benzylthiazolidin-2-ylidene)-1,3-dimethyl hexahydropyrimidin-2,4,6-trione
having agricultural activity. Andre Roland et. al.410 demonstrated some
barbituric acid derivatives used as herbicidal and insecticides.
Omar M. T.411 has synthesised barbitone derivatives, showing antimicrobial
activity. Sakai et. al.412 have synthesised new barbitones which were assessed
for bone and cartilage disease. Ambrogio Oliva et. al.413 have synthesised
barbitones possessing antimetastatic and antitumor activity. Weber W et. al.414
have synthesised barbitones as main metabolite (VI). Frank Grams et. al.415
have synthesised barbitones and found to be metalloprotease inhibitors. R T
Pardasani et. al.416 have synthesised new barbitones for antibacterial agents.
(VII).
Levesque D. L. et.  al .417 have synthesised barbitones as uridine
phosphoralase inhibitors. Wyzlic I. M. et. al.418 have synthesised and tested
barbitones as anticonvulsant agent. Shivanyuk A. N. and co-worker419 have
prepared barbitones as Porphyrin Melamine Calixarene receptor. Gursu Esin
et. al.420 have prepared barbitone as biological activity agent. Bosies Elmar






















Abdel Hamide S. G. et. al.422 have prepared barbitone as anticonvulsant
agent (IX). Li Laizhong et. al.423 have synthesised barbitones and screened for
their anticonvulsant activity.
Recently, Geppert Dangmar et. al.424 have synthesised barbitones and
tested their metalloproteinase inhibitory activity.
These observations led us to explore barbitone chemistry by synthesising
its derivatives in order to achieve better therapeutic agents. It has been described
as under.



























R1, R2 = H, Halo, R3 = CH3, Et, Ph
Barbitones... 124
SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 5-[1'-ARYL-3'-(1''N,3''-
DIPHENYL-4''-PYRAZOLYL)-PROP-2'-ENYLIDINE]-BARBITURIC ACIDS
Barbiturates have received considerable attention in the field of medicinal
chemistry due to wide range of pharmaceutical activities exhibited by them.
Prompted by these facts, the preparation of barbitone of type (VIII) was carried
out by the reaction of chalcone of type (I) with barbituric acid in glacial acetic
acid.
The constitution of the synthesised products have been characterised by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and mass spectrometry also. In mass spectrometry the m/z value
indicate the molecular weight, i .e. when R=4-Bromophenyl, molecular
weight=539, m/z=541 (m+2).
All the compounds have been also evaluated for their antibacterial activity
towards Gram positive and Gram negative bacterial strains and antifungal activity
towards Aspergillus niger at a concentration of 40µg/ml. The biological activity
of the synthesised compounds have been compared with standard drugs. Some
compounds have been found to have good and equivalent activity as compared













R = ArylType (VIII)
125
126
IR SPECTRAL STUDY OF 5-[1'-(p-ANISYL)-3'-(1"N,3"-DIPHENYL-4"-PYRAZOLYL)-
PROP-2'-ENYLIDINE]-BARBITURIC ACID
I
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Aromatic C-H str. (sym.) 3055 3090-3030 671
C=C str. 1525 1585-1480 "
C-H i.p. def. 1016 1125-1000 "
C-H o.o.p. def. 830 835-810 "
Pyrazole C=N 1598 1640-1600 673
moiety C-N 1203 1230-1020 "
Barbitone N-H str. 3209 3350-3200 670
ring -C=O str. 1739 1750-1680 "
-C=O str. 1691 1750-1680 "
C-H str. (sym.) 2850 2950-2850 "















































PMR SPECTRAL STUDY OF 5-[1'-(p-ANISYL)-3'-(1"N,3"-DIPHENYL-4"-PYRAZOLYL)-
PROP-2'-ENYLIDINE]-BARBITURIC ACID
Internal Standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity Inference J Value
No. (δ ppm) of Protons In Hz
1 3.86 3H singlet Ar-OCH3 -
2 6.92-6.96 2H doublet CHcc' J=8.9
3 7.31-7.39 2H doublet CH jk -
4 7.43-7.52 5H multiplet CHa -
5 7.69-7.72 2H doublet CH d,h -
6 7.77-7.81 2H doublet CH e,g -
7 7.85-7.91 1H doublet CHf -
8 7.94-7.96 2H doublet CH bb' J=8.9
9 8.34 1H singlet CHi -












































































































































S B -  2 2
EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 5-[1'-ARYL-3'-(1''N,3''-
DIPHENYL-4''-PYRAZOLYL)-PROP-2'-ENYLIDINE]-BARBITURIC ACIDS
[A] Synthesis of N-Phenylamino-α-methyl-phenyl azomethine
See [A] Part-I, Section-I (A).
[B] Synthesis of 1N,3-Diphenyl-4-formyl pyrazole
See [A] Part-I, Section-I (B).
[C] Synthesis of 1-(p-Anisyl)-3-[1'N,3'-diphenyl-4'-pyrazolyl]-2-propene-
1-one
See [A] Part-I, Section-I (C).
[D] Synthesis of 5-[1'-(p-Anisyl)-3'-[1''N,3"-diphenyl-4"-pyrazolyl]-prop-
2-enylidine]-barbituric acid
A mixture of 1-(p-Anisyl)-3-[1'N,3'-diphenyl-4'-pyrazolyl]-2-propene-1-one
(3.8 g, 0.01 M), barbituric acid (1.28 g, 0.01 M) in glacial acetic acid was refluxed
for 12 hrs. in oil bath. The contents were poured into ice and product was
isolated, crystallized from DMF. Yield, 3.1 g (63%), m.p. 223oC. (C
29
H22N4O4,
Requires: C, 71.02; H, 4.49; N, 11.42%; found : C, 71.05; H, 4.46; N, 11.40%).
TLC solvent system Acetone : Benzene (4:6).
Similarly other barbitones have been prepared. The physical data are
recorded in Table No. 8.
[E] Antimicrobial activity of 5-[1'-Aryl-3'-(1"N,3"-diphenyl-4"-pyrazolyl)-
prop-2'-enylidine]-barbituric acids
Antimicrobial testing was carried out as described in [A] Part-I, Section-I
























8a C6H5- C28H20N4O3 460 118 0.70 59 12.17 12.13
8b 4-Br-C6H4- C28H19N4O3Br 539 178 0.58 68 10.39 10.36
8c 4-Cl-C6H4- C28H19N4O3Cl 494.5 210 0.60 63 11.32 11.30
8d 4-F-C6H4- C28H19N4O3F 478 133 0.54 58 11.71 11.68
8e 4-CH3-C6H4- C29H22N4O3 474 198 0.63 70 11.81 11.80
8f 4-OCH3-C6H4- C29H22N4O4 490 223 0.70 63 11.42 11.40
8g 2-OH-C6H4- C28H20N4O4 476 143 0.58 54 11.76 11.73
8h 4-OH-C6H4- C28H20N4O4 476 178 0.65 71 11.76 11.74
8i 4-NH2-C6H4- C28H21N5O3 475 205 0.57 65 14.73 14.78
8j 3-NO2-C6H4- C28H19N5O3 505 196 0.67 59 13.85 13.81
8k 4-NO2-C6H4- C28H19N5O3 505 192 0.55 68 13.85 13.81
8l 2-C4H3O- C26H18N4O4 450 137 0.69 63 12.44 12.41
8m 2-C4H3S- C26H18N4O3S 466 133 0.53 59 12.01 12.04


































B.mega 12 17 21 11 17 19 13 18 14 17 22 15 16 23 22 24 25 0
s.aureus 12 16 13 17 22 15 12 16 23 11 17 18 15 22 23 17 24 0
E.coli 11 16 13 20 12 17 11 13 18 19 14 21 15 21 21 23 19 0
P.vulgaris 14 13 19 15 16 24 11 17 12 20 12 11 13 15 18 17 20 0
A.niger 16 18 24 17 16 15 23 18 18 19 24 18 16 0 0 0 0 25










COMPARATIVE STUDY OF ANTIMICROBIAL ACTIVITY WITH KNOWN ANTIBIOTICS
[A]
PART-VI
Section - I : Antimicrobial activity of 5-[1'-Aryl-3'-(1"N,3"-diphenyl-4"-pyrazolyl)-prop-2'-enylidine]-barbituric
acids
8c (21) 8e (22) 8d (20) 8c (19) 8c (24)
8k (22) 8i (23) 8l (21) 8j (20) 8g (23)
8k (24)
Ampicillin 23 22 21 15 -
Amoxicillin 22 23 21 18 -
Norfloxacin 24 17 23 17 -
Penicillin 25 24 19 20 -
Greseofulvin - - - - 25
B. mega S. aureus E. coli P. vulgaris A. niger
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity
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The five membered heterocyclic ring system 5-oxo-imidazolines have two
nitrogen atom at 1- and 3-positions and a carbonyl group at 5-position.
The discovery of the 2-substituted-5-imidazolines dates back to the year
1888, when A. W. Hoffman425 for the first time discovered 5-oxo-imidazoline
by heating N'-diacetylethylene diamine in a stream of dry hydrogen chloride.
Moreover, some compounds were prepared by A. Ladenburg426 by the fusion
of two equivalents of sodium acetate with one equivalent of ethylene diamine
dihydrochloride.
SYNTHETIC ASPECT
Various methods have been reported for the synthesis of imidazolinones in
literature427. Aminolysis of oxazolone with amine leads to the formation of
imidazolinones which has been reported in literature428.























2. Allimony et. al.430 have synthesised (II) new imidazolinone derivatives by
conventional method.
3. Feng-Jun-Cai et. al.431 have synthesised 5-imidazolinone derivatives by
microwaves irradiation.
MECHANISM
Azalactone reacts with variety of compounds such as water, alcohols, amines
and hydrogen halides. Amides of α-acylamino acryclic acids obtained from the
condensat ion of  aza lac tone and pr imary amine can be conver ted to
imidazolinones as shown in equation (III).
The ring closer can be effected under a variety of conditions. Substituted
anilides have been converted to imidazolinone derivatives by the  action of
POCl3.
THERAPEUTIC IMPORTANCE
Naphazoline hydrochloride, xylometazoline hydrochloride etc. are various
imidazolinone derivatives which have been used as adrenergic stimulants and
tolazol ine and phenotolamine as adrenergic  b locking agents .  Var ious


























R' - NH2, Dry C5H5N / Abs. C2H5OH, K2CO3
1. Antitubercular432

















K. K. Awasthi et. al.458 (IV) have synthesised some new imidazolinone
derivatives and reported their antimicrobial activity.
Farmshow Christopher Geoffrey et. al.459 and Pilkington et. al.460 have








and co-worker461 have prepared substituted imidazolinones which inhibited
the abnormal cell growth in human body. Stefama Lauter and Co-worker462
have isolated imidazoline from different methods and tested for the treatment
of cytokine release. Imidazoline derivatives have been prepared by Declera-
Arthur and co-worker463 showing anti-HIV activity. Ding, Ming-Wu et. al.464
have prepared novel imidazolines and reported their antifungal activity.
Kolhe Vishnu et. al.465 have reported anti-AIDS, antibacterial and
fungicidal activity of 5-oxo-imidazolines. B. R. Shah and co-worker466 have
prepared some new imidazolines and reported anticancer and anti HIV activity.
U. Akyoshi et. al.467 have prepared some new imidazolinone derivatives
(V) and reported their herbicidal activity. Agrochemical activity of imidazolinones
have been reported by Bascou and co-workers468.























CONTRIBUTION FROM OUR LABORATORY
Parikh et. al.470 have synthesised imidazolinones bearing thiazole as
moderately active bactericidal and fungicidal. H. H. Parekh et. al.471 have
elaborated better activity for some imidazolinones with activated benzylidene
group at 5-position.
Recently, Dr. H. H. Parekh et. al.472 suggested imidazolinones as a
antitubercular, anticancer (VII).
H. H. Parekh and co-worker have synthesised imidazolinone derivatives
having isoniazide473 and s-tr iazine474 moiety. Imidazolinones bearing
aminobenzylamino475, chloramphenicol476 and phthalazine477 moiety at 1-
position have been demonstrated as a antimicrobial agents by A. R. Parikh and
co-workers (VIII).


























A. R. Parikh et. al. have synthesised imidazolinones bearing phthalazine478,
2-base of chloramphenicol479 moiety at one position which were evaluated for
their antimicrobial activity. Parikh et. al.480 have reported 4-(4'-Arylidine-2'-
phenyl-5'-oxo-imidazolin-1-yl) benzophenones which were screened for their
antimicrobial activity. Biplabde et. al.481 have reported some new 5-oxo-
imidazoline as antimicrobial agents. Imidazolinones have been reported to
possess antioxidant activity.
Moreover, A. R. Parikh, H. H. Parekh and co-workers have synthesised the
newer 5-oxo-imidazolines with different variety of activities described as under.
v 1-p-(4'-Acetamidobenzenesulphonamido) phenyl-2-phenyl-4-substituted
benzal-5-oxoimidazolines482.
v Synthesis of biologically active 5-oxo-imidazolines483-485.
v Preparation and antimicrobial activity of 1-N-Aryl-2-methyl-4'-(8-hydroxy
quinolin-7'-yl)-methine-5-oxoimidazolines486.
v Synthesis of some 5-imidazolinones as novel bioactive compounds derived
from benzimidazole487.
















Moreover Yoneda Naoto et. al.489 have synthesised imidazolinones as
antihypertensive agent. R. C. Dage et. al.490 have synthesised cardiotonic
imidazolones. Armando Rossello et. al.491 have synthesised imidazolones as
antifungal agent. Cooper A. B. and co-workers492 have found that imidazolones
are inhibitors of farnesyl proteing transferase. Machii Daisuke et. al.493 have
synthesised new imidazolones as a telomerase inhibitors and antitumor agents.
Jean M. R. et. al.494 have synthesised imidazolones and tested as antileishmanial
agent. Chafiq Hamdouchi et. al.495 have synthesised imidazolinones and
screened for their potent and broad spectrum activity. Irene M. L. et al.496
have synthesised imidazolinones and tested as antireteroviral activity (IX).
Xu Zhi-Feng et. al.497 have synthesised imidazolinones as biological agent.
With a view to getting better therapeutic agent, it was contemplated to
synthesise imidazolinones to enhance the overall activity of resulting compounds
which have been described as under.















SYNTHESIS AND BIOLOGICAL EVALUATION OF 1N-ARYL-2-ALKYL/
ARYL-4-[1'N,3'-DIPHENYL-4'-PYRAZOLYLMETHINO]-IMIDAZOLIN-5-
ONES
Imidazolinones represent one of the most active classe of compounds having
a wide spectrum of biological activities with an aim to getting better therapeutic
agent. The preparation of 5-oxo-imidazolines of type (IX) have been undertaken
by the condensation of azalactone with different aromatic amines as shown in
reaction scheme.
The constitution of the synthesised products have been characterised by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and further supported by mass spectrometry. In mass spectrometry
the m/z value indicate the molecular weight, i.e. when R=4-nitrophenyl,
molecular weight=511, m/z=510 (m-1).
All the compounds have been also evaluated for their antibacterial activity
towards Gram positive and Gram negative bacterial strains and antifungal activity
towards Aspergillus niger at a concentration of 40 µg/ml. The biological activity
of the synthesised compounds have been compared with standard drugs. Some
compounds have been found to have good and equivalent activity as compared













































IR SPECTRAL STUDY OF 1N-(o-CHLOROPHENYL)-2-PHENYL-4-[1'N,3'-DIPHENYL-
4'-PYRAZOLYLMETHINO]-IMIDAZOLIN-5-ONE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Aromatic C-H str. 3057 3090-3030 673
C=C str. 1504 1585-1480 "
C-H i.p. def. 1060 1125-1000 "
C-H o.o.p. def. 808 835-810 "
Pyrazole C=N str. 1596 1650-1580 672
moiety C-N str. 1201 1220-1020 "
Imidazolinone C=O str. 1718 1760-1655 670
ring C=N str. 1639 1650-1580 "
C-N str. 1253 1260-1220 "
C=C str. 2923 2950-2850 "











































PMR SPECTRAL STUDY OF 1N-PHENYL-2-METHYL-4-[1 'N,3' -DIPHENYL-4'-
PYRAZOLYLMETHINO]-IMIDAZOLIN-5-ONE
Internal Standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity Inference
No. (δ ppm) of Protons
1 2.26 3H singlet -CH3
2 7.17-7.22 1H triplet CHd
3 7.25 1H singlet CHm
4 7.35-7.59 10H multiplet CH a,e,c,h,j,i
5 7.67-7.70 2H multiplet CH g,k







































































































































































S B -  1 1
EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 1N-ARYL-2-ALKYL/
ARYL-4-[1'N,3'-DIPHENYL-4'-PYRAZOLYLMETHINO]-IMIDAZOLIN-5-
ONES
[A] Synthesis of 1N,3-Diphenyl-4-formyl-pyrazole
See [A] Part-I, Section-I (B).
[B] Synthesis of 2-Methyl-4-[1'N,3'-diphenyl-4'-pyrazolylmethino]-
oxazolin-5-one
A mixture of 1N,3-Diphenyl-4-formyl pyrazole (6.2 g, 0.025 M), acetic
anhydride (7.6 g, 0.075 M) and sodium acetate (2.0 g) was heated on a waterbath
for 4 hrs. Resulting mass was poured into ice cold water, filtered and crystallised
from DMF. Yield, 65% (2.1 g), m.p. 194oC.
[C] Synthesis  o f  1N-Phenyl -2-methyl -4- [1 'N,3 ' -d iphenyl -
4'-pyrazolylmethino]-imidazolin-5-one
A mixture of 2-Methyl-4-[1'N,3'-diphenyl-4'-pyrazolyl-methino]-oxazolin-
5-one (3.27 g, 0.01 M) and aniline (0.93 g, 0.01 M) in dry pyridine (20 ml) was
refluxed for 12 hrs. in oil bath. Resulting mass was poured into crushed ice and
neutralised with HCl, filtered and crystallised from dioxan. Yield, 2.8 g, (69%),
mp. 123oC. (C20H20N4O ; Requires : C, 59.41; H, 4.95; N, 13.85%; found : C,
59.40; H, 4.90; N, 13.80%). TLC solvent system Acetone : Benzene (4:6).
Similarly other imidazolin-5-one have been prepared. The physical
constants are recorded in Table No. 9.
[D] Antimicrobial activity of 1N-Aryl-2-alkyl/aryl-4-[1'N,3'-diphenyl-4'-
pyrazolylmethino]-imidazolin-5-ones
Antimicrobial activity was carried out as described in [A] Part-I, Section-I










9a C6H5- -CH3 C20H20ON4 404 123 0.68 69 13.85 13.83
9b 4-Cl-C6H4- -CH3 C26H19ON4Cl 438.5 163 0.55 67 12.77 12.70
9c 4-NO2-C6H4- -CH3 C26H19O3N5 449 196 0.71 68 15.58 15.53
9d C6H5- -C6H5 C31H22ON4 446 213 0.63 65 12.01 12.03
9e 2-CH3-C6H4- -C6H5 C32H24ON4 480 185 0.57 61 11.66 11.62
9f 4-CH3-C6H4- -C6H5 C32H24ON4
480 173 0.65 75 11.66 11.63
9g 2-OCH3-C6H4- -C6H5 C32H24O2N4 496 210 0.54 68 11.28 11.23
9h 4-OCH3-C6H4- -C6H5 C32H24O2N4 496 196 0.64 60 11.28 11.24
9i 4-F-C6H4- -C6H5 C31H21ON4F 484 178 0.55 63 11.56 11.51
9j 2-Cl-C6H4- -C6H5 C31H21ON4Cl 500 183 0.70 73 11.18 11.13
9k 2-NO2-C6H4- -C6H5 C31H21O3N5 511 193 0.58 68 13.69 13.71
9l 3-NO2-C6H4- -C6H5 C31H21O3N5 511 211 0.71 66 13.69 13.63
9m 4-NO2-C6H4- -C6H5 C31H21O3N5 511 218 0.63 71 13.69 13.65
*TLC Solvent System : 9a, 9b, 9c, 9f, 9g, 9k, 9j : Acetone : Benzene (4 : 6).
















































B.mega 11 17 20 13 18 11 15 16 19 21 14 12 18 23 22 24 25 0
s.aureus 16 18 12 17 22 16 12 19 20 13 11 15 17 22 23 17 24 0
E.coli 16 12 13 23 14 17 13 17 18 19 15 16 20 21 21 23 19 0
P.vulgaris 11 18 17 13 15 17 19 14 17 18 20 13 16 15 18 17 20 0
A.niger 15 14 23 18 19 15 23 12 13 20 14 14 22 0 0 0 0 25













COMPARATIVE STUDY OF ANTIMICROBIAL ACTIVITY WITH KNOWN ANTIBIOTICS
[A]
PART-VII
Section - I : Antimicrobial activity of 1N-Aryl-2-alkyl/aryl-4-[1'N,3'-dipheyl-4'-pyrazolylmethino]-imidazolin-
5-ones
9c (20) 9e (22) 9d (23) 9g (19) 9c (23)
9j (21) 9i (20) 9m (20) 9k (20) 9g (23)
9m (22)
Ampicillin 23 22 21 15 -
Amoxicillin 22 23 21 18 -
Norfloxacin 24 17 23 17 -
Penicillin 25 24 19 20 -
Greseofulvin - - - - 25
B. mega S. aureus E. coli P. vulgaris A. niger
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity
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Thiazolidinones, which belong to an important group of heterocyclic
compounds have been extensively explored for their applications in the field of
medicine. Thiazolidinones, with a carbonyl group at position 2 (I), 4 (II) or 5 (II)
have been subjected of extensive study in the recent past. Numerous reports
have appeared in the literature which highlight their chemistry and use.
4-Thiazolidinones are derivatives of thiazolidine with carbonyl group at 4-
position (II). Substituent in the 2, 3 and 5 positions may be varied, but the
greatest different in structure and properties is exerted by the groups attached
to carbon atom at the 2-position and to nitrogen atom at the 3-position. The
cyclic structure was assigned after recognisation of mercaptoacetic acid as a
primary product of hydrolysis of 3-phenyl-2-phenylimino-4-thiazolidinones498.
SYNTHETIC ASPECT
Several method for the preparation of 4-thiazolidinones are narrated in
literature499-507
1. R. Nath and K. Shanker508 have prepared 4-thiazolidinone by cyclization

































































































2. I. D. Shah and J. P. Trivedi509 synthesised thiazolidinones from 4-aryl
th iosemicarbazones  by condens ing them wi th  ch loroacet ic  ac id ,
α-bromopropionic and α-bromophenyl acetic acid.
3. M. Seeda et. al.510 have synthesised some new thiazolidinones.
MECHANISM
The reaction of 4-thiazolidinones proceeds by the attacks of the chloroacetic
acid upon the C=S group, the tautomerism takes place with removal of HCl
followed by removal of water and subsequent cyclization.
R = Aryl
THERAPEUTIC IMPORTANCE
Much research has been carried out with the aim to finding therapeutic
values of thiazolidinone moiety since their discovery. The thiazolidinones,


















Hassan et. al.536 have prepared 2-imino-4-thiazolidinones which have been
found to possess antimicrobial activity. K. Mogilaiah and co-workers537,538
isolated some 4-thiazolidinone derivatives and tested their antibacterial activity.
G. S. Godaginamath et. al.539 also prepred thiazolidinone derivatives as
antimicrobial agent. R. S. Lodhi and co-worker540 have been synthesised and
s tud ied ant imicrob ia l ,  an t i in f lammatory  and ana lges ic  proper ty  o f
4-thiazolidinone and arylidene derivatives (VIII).
Thiazolidinones... 153
Pawar and co-worker541 reported synthesis and in vitro antibacterial
activity of some 4-thiazolidinone derivatives. Goel et al.542 have synthesised
thiazolidinone derivatives and compared their antiinflammatory activity,
ulcerogenic liability, cardiovascular and CNS effects. In other study, some
thiazolidinones have been found to be promising antibacterial agent543,544.
Siddique, Mohammed et. al.545 have prepared substituted thiazolidinones
and reported their antinbacterial, antifungal, antithyroid and amoebicidal
properties (IX).
CONTRIBUTION FROM OUR LABORATORY
Parikh et. al. have used diphenylsulphone546,547, substituted aryl548-
558,  arsenoic  ac id559,  2-ary l -1 ,3 ,4- th iad iazo le560,  2-benzy l -1 ,3 ,4-
th iad iazo l561,562,  p ico l iny lamino563,  s - t r iaz ine564,  benzoy lamino
acetamido565, sulphonamidobenzoylamino566, phthalazin-1-yl-amino567,








ZO R1 = (un) substituted aryl
Z = H2
Z = CH2R2










R1 = OH; R2, R4, R5 = H; R3 = Me
(VIII)
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th iazo l id inone wi th  subs t i tu ted ary l ,  subs t i tu ted hydroxy ary l ,  β ,β ' -
dichloroethylaminophenyl, 8-hydroxyquinolinyl moiety at 2-position (R) of 4-
thiazolidinone ring system.
H. H. Parekh and co-workers have synthesised 4-thiazolidinones having
dapson568-573, s-triazine574-577, acridin578,579, thymoloxyacetamido580,
6-hydroxypyridine581,582 moiety at 3-position (X) of 4-thiazolidinone ring
system.
Parikh A. R. et. al.583 have reported bactericidal and fungicidal activity of
4-thiazolidinones, Parekh & co-worker584 have synthesised 2-Aryl-3-p-
acetamidophenoxyacetamido-5H/methyl-4-thiazolidinones which showed
antitubercular activity.



































Akama Tsutoma et. al.585 have synthesised thiazolidinones as a Telomerase
inhibitors. S. Guniz Kucukguzel et. al.586 have synthesised thiazolidinone as
antimicrobial and anticancer agent. S. K. Srivastava et. al.587 have prepared
new thiazolidinone as antibacterial, antifungal, analgesic and diuretic agents.
Recently, Fujiwara Norio et. al.588 have synthesised thiazolidinones as
antiinflammatory agent. Pfahl Magnus et. al.589 have synthesised thiazolidinones
and tested their phosphatase inhibitory and anticancer activity. Jag Mohan et .
al.590 have prepared antimicrobial thiazolidinones (X).
Govindara jan R.  e t .  a l .591  have synthes i sed th iazo l id inones  as
antitubercular, antifungal and antibacterial agent. Dinh T. T. H et. al.592 have
prepared antibacterial and antifungal thiazolidinones. Takagi Masae and
co-worker593 have synthesised thiazol idinones and screened for their
antiinflammatory activity. Ma Tonghui et. al.594 have synthesised thiazolidinones
as CFTR (cystic fibrosis transmembrane conductance regulator) inhibitor.
These valid observations led us to explore thiazolidinone chemistry by
synthesising its derivatives bearing pyrazole moiety of medicinal value in order
to achieve better therapeutic agents. It has been described in the following
section.
SECTION - I : SYNTHESIS AND BIOLOGICAL EVALUATION OF










(IX) R = H, alkyl
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-ARYLIMINO-3N-
A R Y L - 5 - [ 1 ' N , 3 ' - D I P H E N Y L - 4 ' - P Y R A Z O LY L M E T H I N O ] -
4-THIAZOLIDINONES
With a view to getting better therapeutic agents and considering the
association of various biological activities of thiazolidinone heterocycles, the
preparation of arylidenes of type (X) have been undertaken by the condensation
of 1N,3-Diphenyl-4-formyl pyrazole with different 2-Arylimino-3N-aryl-5H-4-
thiazolidinones.
The constitution of the synthesised products have been characterised by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and mass spectrometry also. In mass spectrometry the m/z value
indicate the molecular weight, i.e. when R=p-Tolyl, molecular weight=526, m/
z=527 (m+1).
All the compounds have been also evaluated for their antibacterial activity
towards Gram positive and Gram negative bacterial strains and antifungal activity
towards Aspergillus niger at a concentration of 40µg/ml. The biological activity
of the synthesised compounds have been compared with standard drugs. Some
compounds have been found to have good and equivalent activity as compared








Type (X) R = Aryl
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REACTION SCHEME







































IR SPECTRAL STUDY OF 2-p-TOLYLIMINO-3N-(p-TOLYL)-5-[1'N,3'-DIPHENYL-
4'-PYRAZOLYLMETHINO]-4-THIAZOLIDINONE
I
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C-H str. (sym.) 2920 2975-2950 670
C-H str. (asym.) 2852 2880-2860 "
C-H i.p. def. 1442 1470-1435 "
C-H o.o.p. def. 1365 1395-1370 "
Aromatic C-H str. 3020 3090-3030 672
C=C str. 1502 1585-1480 "
C-H i.p. def. 1109 1125-1000 "
C-H o.o.p. def. 817 835-810 "
Pyrazole C=N str. 1598 1640-1600 671
moiety C-N str. 1211 1230-1020 "
Thiazolidinone C=O str. 1706 1760-1655 675
ring C-S-C str. 617 700-600 "
C-O-C str. (sym.) 1018 1075-1020 "
C-O-C str. (asym.) 1269 1275-1200 "
C-N str. 1143 1220-1020 "



















































PMR SPECTRAL STUDY OF 2-p-TOLYLIMINO-3N-(p-TOLYL)-5-[1'N,3'-DIPHENYL-
4'-PYRAZOLYLMETHINO]-4-THIAZOLIDINONE
Internal Standard : TMS; Solvent : DMSO.d6 + CDCl3 ; Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity Inference J Value
No. (δ ppm) of Protons In Hz
1 2.35 3H singlet Ar-CH3 -
2 2.41 3H singlet Ar-CH3 -
3 6.84-6.87 2H doublet CHaa' J=8.7
4 7.15-7.18 2H doublet CHbb' J=8.7
5 7.33 4H singlet CH c,c'd,d' -
6 7.35 1H doublet Chg -
7 7.45-7.53 5H multiplet CHj -
8 7.64-7.67 2H doublet CH f,h -
9 7.72 1H singlet CHl -
10 7.8-7.85 2H triplet CH e,i -












































































































m/z = 527 (M + 1)










S B -  6
EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-ARYLIMINO-
3 N -A RY L - 5 - [ 1 ' N , 3 ' - D I P H E N Y L - 4 ' -P Y R A Z O LY L M E T H I N O ] -
4-THIAZOLIDINONES
[A] Synthesis of N-Phenylamino-α-methyl-phenyl azomethine
See [A] Part-I, Section-I (A).
[B] Synthesis of 1N,3-Diphenyl-4-formyl pyrazole
See [A] Part-I, Section-I (B).
[C] Synthesis of Bis-p-tolylthiourea595
A mixture of p-toludine (2.14 g, 0.02 M) and carbondisulphide (0.76 g,
0.01 M) in absolute ethanol was heated at 40oC in waterbath for 12 hrs. The
product solidified on completion of reaction, the excess of the solvent was
removed by distillation. The crude product was treated with dil. HCl, isolated
and crystal l ised from rect i f ied spir i t .  Yield, 4.1 g (80%), m.p. 154oC.
(C15H16N2S; Requires C, 70.31; H, 6.25; N, 10.93%; found : C, 70.32;
H, 6.27; N, 10.95%).
[D] Synthesis of 2-p-Tolylimino-3-(p-tolyl)-5H-4-thiazolidinone596
A mixture of Bis-p-tolylthiourea (2.54 g, 0.01 M), chloroaceticacid (0.95 g,
0.01 M) and sodium acetate (1.23 g, 0.015 M) in glacial acetic acid (30 ml) was
refluxed in oil bath for 10 hrs. The reaction product was poured into ice, kept
overnight, crude product was isolated, crystallised from glacial acetic acid.
Yield, 2.35 gm (80%), m.p. 145oC. (C17H16N2OS; Requires C, 68.91; H, 5.40;
N, 9.45%; found : C, 68.92; H, 5.44; N, 9.47%).
163
[E] Synthesis of 2-p-Tolylimino-3N-(p-tolyl)-5-[1'N,3'-diphenyl-4'-
pyrazolylmethino]-4-thiazolidinone
A mixture of  1N,3-Diphenyl-4- formyl  pyrazole (2.48 g,  0.01 M),
2-p-tolylimino-3-(p-tolyl)-5H-4-thiazolidinone (2.96 g, 0.01 M) and fused sodium
acetate  (0.9 g, 0.01 M) in glacial acetic acid was refluxed for 8 hrs. The solid
thus obtained was f i l tered,  washed, dr ied and crysta l l i zed from DMF.
Yield, 3.7 g (71%) , m.p. 210oC. (C33H26N4OS ; Requires : C, 75.29; H, 4.94;
N, 10.64%; found : C,75.32; H, 4.90; N, 10.67%). TLC solvent system,
Acetone : Benzene (2:8).
Similarly other arylidines or thiazolidinones were prepared. The physical
data are recorded in Table No. 10.
[F] Antimicrobial activity of 2-Arylimino-3N-aryl-5-[1'N,3'-diphenyl-4'-
pyrazolylmethino]-4-thiazolidinones
Antimicrobial testing was carried out as described in [A] Part-I, Section-I
























10a C6H5- C31H22N4OS 498 193 0.58 83 11.24 11.23
10b 2-Cl-C6H4- C31H20N4OSCl2 567 196 0.56 73 10.51 10.50
10c 4-Cl-C6H4- C31H20N4OSCl2 567 188 0.65 64 10.51 10.48
10d 4-F-C6H4- C31H20N4OSF2 534 192 0.54 62 10.49 10.53
10e 2-CH3-C6H4- C33H26N4OS 526 186 0.61 68 10.64 10.65
10f 3-CH3-C6H4- C33H26N4OS 526 143 0.63 70 10.64 10.63
10g 4-CH3-C6H4- C33H26N4OS 526 210 0.49 71 10.64 10.67
10h 2-OCH3-C6H4- C33H26N4O3S 558 219 0.65 69 10.03 10.01
10i 4-OCH3-C6H4- C33H26N4O3S 558 188 0.70 63 10.03 10.07
10j 4-COOH-C6H4- C33H22N4O5S 586 185 0.70 75 9.55 9.53
10k 2-NO2-C6H4- C31H20N6O5S 588 180 0.52 65 14.28 14.29
10l 3-NO2-C6H4- C31H20N6O5S 588 173 0.51 64 14.28 14.25
10m 4-NO2-C6H4- C31H20N6O5S 588 195 0.63 63 14.28 14.30











GRAPHICAL CHART NO. 10 :      ANTIMICROBIAL ACTIVITY OF  2-ARYLIMINO- 3N-ARYL-5-[1’N,3’-DIPHENYL-






















B.mega 11 15 17 22 16 18 12 17 19 20 13 21 14 23 22 24 25 0
s.aureus 14 22 15 19 17 16 18 22 17 12 23 19 18 22 23 17 24 0
E.coli 19 18 12 20 13 11 16 21 15 13 19 14 17 21 21 23 19 0
P.vulgaris 12 19 13 20 14 15 15 14 16 13 17 12 18 15 18 17 20 0
A.niger 13 21 11 13 17 20 16 15 12 19 17 13 18 0 0 0 0 25













COMPARATIVE STUDY OF ANTIMICROBIAL ACTIVITY WITH KNOWN ANTIBIOTICS
[A]
PART-VIII
Section - I :  Antimicrobial activity of 2-Arylimino-3N-aryl-5-[1'N,3'-diphenyl-4' -pyrazolylmethino]-4-
thiazolidinones
10d (22) 10b (22) 10d (20) 10b (19) 10b (21)
10j (20) 10h (22) 10h (21) 10d (20) 10f (20)
10l (21) 10k (19) 10m (18)
Ampicillin 23 22 21 15 -
Amoxicillin 22 23 21 18 -
Norfloxacin 24 17 23 17 -
Penicillin 25 24 19 20 -
Greseofulvin - - - - 25
B. mega S. aureus E. coli P. vulgaris A. niger
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity
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Nitriles are reported to possess various therapeutic activities, but due to
their high toxicity, they have low therapeutic importance. The term 'Nitrile' was
first introduced by Febung597 in 1844. The first synthesis of nitrile has been
reported by Wohler and Liebig598 in 1832 and Poleuze599 in 1834. They are
very much useful as intermediates for various products such as acrylonitrile for
plastic, synthetic rubber and fibers, phthalonitrile for dye stuff.
SYNTHETIC ASPECT
D. Mowry600 reviewed various methods of preparation of nitriles. Few
recent methods are as mentioned below.
1. From halides using NaCN; Al2O3
601
2. From alkylhalides using KCN tetra alkyl ammonium salt602 and water in
trace.
3. The pyrolysis of schiff's base603
4. Mohanakrishna A. K. and co-worker604 have synthesised nitrile derivatives









The mechanism of nitrile is shown as under.
THERAPEUTIC EVALUATION
They shows various therapeutic activities, which are described as under.
1. Antihypertensive605







Cardenolide nitrile showed moderate biological activity in rats613. Nitriles,
with fused pyridine ring were reported as elcer inhibitor614. Kobayashi Shigco
et. al.615 have synthesised new derivatives of nitriles. M. C. Dougal616 have
synthesised nitriles and studied their pharmacological activities. Lai Hio Kiong
























Volmajer Juliya et. al.618 synthesised some new nitriles and reported them
as anticonvulsant agent. Shibata Yasushi and co-workers619 have synthesised
nitrile derivatives associated with insecticides. Nosyrava et. al.620 have prepared
novel nitriles which have been shown to possess muscle relaxant activity. Yagihara
and co-workers621 have prepared nitriles which possess antimicrobial and
antiinflammatory activity. Parlo Sanna et. al.622 have synthesised nitriles and
screened for their antitubercular activity (III). Iwanowicz E. J. et. al.623 have
prepared nitriles and found to preventing and treating IMPDH-associated
disorders, such as transplant rejection and autoimmune disease.
Collin Xavier and co-workers624 have synthesised antifungal acetonitriles.
Bhatnagar Neerja et. al.625 have synthesised nitriles as inhibitors of Cathepsin
K. Bernard M. et. al.626 have synthesised nitriles as thromboxane receptor
antagonists. Alwal K. S. et. al.627 have prepared nitriles as inhibitors of
mitochondrial F1 F0 ATpase.
Recently, Mura Kami Hiroshi et. al.628 have synthesised some new nitriles
and screened for their pesticidal and marin antifouling activity (V).
R = cycloalkyl, alkyl, alkenyl





















CONTRIBUTION FROM OUR LABORATORY
F. M. Bharmal, D. J. Kaneria and H. H. Parekh629 have synthesised newer
acetonitriles bearing quinoline moiety and tested as antimicrobial agents (VI).
Looking to the interesting properties of nitriles, we have synthesised some
new nitriles, which have been described as under.





















SYNTHESIS AND BIOLOGICAL EVALUATION OF α-ARYLAMINO-
[1'N,3'-DIPHENYL-4'-PYRAZOLYL]-ACETONITRILES
In view of therapeutic activities of nitriles, it was contemplated to synthesise
some new nitriles in search of agents possessing higher biological activity. Nitriles
of type (XI) have been synthesised by the reaction of 1N,3-Diphenyl-4-formyl-
pyrazole with different aromatic amines by the presence of potassium cyanide
and glacial acetic acid at 0-5oC.
The constitution of the synthesised products have been characterised by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and mass spectrometry also. In mass spectrometry the m/z value
indicate the molecular weight, i.e. when R=p-Tolyl, molecular weight=364,
m/z=365 (m+1).
All the compounds have been also evaluated for their antibacterial activity
towards Gram positive and Gram negative bacterial strains and antifungal activity
towards Aspergillus niger at a concentration of 40µg/ml. The biological activity
of the synthesised compounds have been compared with standard drugs. Some
compounds have been found to have good and equivalent activity as compared










R-NH2, KCN, 0-5  C
o
Type (XI) R = Aryl
172
173
IR SPECTRAL STUDY OF α-(p-TOLYLAMINO)-[1'N,3'-DIPHENYL-4'-PYRAZOYL]-
ACETONITRILE
I
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C-H str. (sym.) 2916 2975-2950 670
C-H str. (asym.) 2854 2850-2740 "
C-H def. (asym.) 1409 1470-1435 "
C-H def. (sym.) 1365 1390-1370 "
Aromatic C-H str. 3045 3090-3030 672
C=C str. 1521 1520-1480 "
C-H i.p. def. 1122 1125-1090 "
C-H o.o.p. def. 812 835-810 "
Pyrazole C=N str. 1596 1640-1590 673
moiety C-N str. 1058 1120-1020 "
Nitrile C=N str. 2229 2240-2220 674










































PMR SPECTRAL STUDY OF α-(p-TOLYLAMINO)-[1'N,3'-DIPHENYL-4'-PYRAZOLYL]-
ACETONITRILE
Internal Standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity Inference J Value
No. (δ ppm) of Protons In Hz
1 2.3 3H singlet Ar-CH3 -
2 5.39 1H singlet CHn -
3 6.7-6.73 2H doublet CH bb' J=8.4
4 7.09-7.2 2H doublet CH aa' J=8.4
5 7.32-7.37 1H multiplet CHj -
6 7.39-7.47 3H multiplet CH e,f,d -
7 7.49-7.52 2H triplet CH c,g -
8 7.7-7.79 4H doublet CH h,i,k,l -




































































































S B -  5
EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF α-ARYLAMINO-
[1'N,3'-DIPHENYL-4'-PYRAZOLYL]-ACETONITRILES
[A] Synthesis of N-Phenylamino-α-methyl-phenyl azomethine
See [A] Part-I, Section-I (A).
[B] Synthesis of 1N,-3-Diphenyl-4-formyl pyrazole
See [A] Part-I, Section-I (B).
[C] Synthesis of α-(p-Tolylamino)-[1'N,3'-diphenyl-4'-pyrazolyl]-
acetonitrile
1N,3-Diphenyl-4-formyl-pyrazole (2.48 g, 0.01 M) dissolved in ethanol
(25 ml) was added to potassium cyanide (0.64 g, 0.01 M) disolved in water
(5 ml) followed by glacial acetic acid (5 ml). The contents were then stirred for
5 minutes to form cyanohydrin at 0oC. p-Toludine (1.07 g, 0.01 M) dissolved in
methanol was added to the reaction mixture, contents were kept at room
temperature for 24 hrs. and poured into ice. The solid product was crystallized
from ethanol. Yield, 2.5 gm (69% ), m.p. 174oC. (C24H20N4;  Requires :
C, 79.12; H, 5.49; N, 15.37%; found : C, 79.10; H, 5.46; N, 15.34%). TLC
solvent system Acetone : Benzene (3:7).
Similarly other nitriles were prepared. The physical data are recorded in
Table No. 11.
[D] Antimicrobial activity of α-Arylamino-[1'N,3'-diphenyl-4'-pyrazolyl]-
acetonitriles
Antimicrobial testing was carried out as described in [A] Part-I, Section-I
























11a C6H5- C23H18N4 350 118 0.58 81 15.99 15.94
11b 3-CH3-C6H4- C24H20N4 364 179 0.63 77 15.37 15.36
11c 4-CH3-C6H4- C24H20N4 364 174 0.49 69 15.37 15.34
11d 2,3-(CH3)2-C6H3- C25H22N4 378 211 0.64 65 14.80 14.73
11e 2-OCH3-C6H4- C24H20ON4 380 186 0.50 68 14.73 14.74
11f 4-OCH3-C6H4- C24H20ON4 380.0 178 0.65 77 14.73 14.71
11g 3-Cl-C6H4- C23H17N4Cl 384.5 210 0.52 69 14.56 14.57
11h 4-Cl-C6H4- C23H17N4Cl 384.5 >230 0.66 73 14.56 14.54
11i 2,5-(Cl)2-C6H3- C23H16N4Cl2 419 205 0.54 75 13.86 13.84
11j 2,6-(Cl)2-C6H3- C23H16N4Cl2 419 196 0.68 78 13.86 13.83
11k 2-NO2-C6H4- C23H17O2N5 395 188 0.56 80 17.71 17.69
11l 3-NO2-C6H4- C23H17O2N5 395 192 0.70 61 17.71 17.68
11m 4-NO2-C6H4- C23H17O2NS 395 209 0.58 65 17.71 17.72


































B.mega 17 19 18 17 14 11 22 12 23 13 16 14 15 23 22 24 25 0
s.aureus 13 17 21 18 16 22 19 15 20 19 12 17 20 22 23 17 24 0
E.coli 13 19 24 20 17 15 16 20 16 13 17 21 18 21 21 23 19 0
P.vulgaris 15 12 17 11 15 14 18 11 15 13 19 16 17 15 18 17 20 0
A.niger 15 17 23 17 14 16 24 15 16 15 23 14 12 0 0 0 0 25










COMPARATIVE STUDY OF ANTIMICROBIAL ACTIVITY WITH KNOWN ANTIBIOTICS
[A]
PART-IX
Section - I : Antimicrobial activity of α-Arylamino-[1'N,3'-diphenyl-4'-pyrazolyl]-acetonitriles
11g (22) 11c (21) 11d (20) 11g (18) 11c (23)
11i (23) 11f (22) 11h (20) 11k (19) 11g (24)
11i (20) 11l (21) 11k (23)
11m (20)
Ampicillin 23 22 21 15 -
Amoxicillin 22 23 21 18 -
Norfloxacin 24 17 23 17 -
Penicillin 25 24 19 20 -
Greseofulvin - - - - 25
B. mega S. aureus E. coli P. vulgaris A. niger
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity
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The microwave region of the electromagnetic spectrum lies between 1 cm
to 1 m and in order to avoid interfering with radar and telecommunication
activities which operate within this region, most domestic and commercial
microwave instruments operate at 2.45 GHz. The heating effect utilized in
microwave assisted organic transformations is due in the main, to dielectric
polarisation, although conduction losses can be important particularly at higer
temperatures whilst the polarisability of a molecule (determined by the Debye
equation) is the sum of a number of contributions, only dipolar and interfacial
polarisation are impor tant to heating effects associated with microwave
irradiation. When a molecule is irradiated with microwaves it rotates to align
itself with the applied field. The frequency of a molecular rotation is similar to
the frequency of microwave radiation and consequently the molecule continually
attempts to realign itself with the changing field and energy is absorbed. It is
particularly convenient that qualitertively, the larger the dielectric constant, the
great the coupling with microwaves. Thus solvents such as water, methanol,
DMF, ethyl acetate, acetone, chloroform, aceticacid and dichloromethane are
all heated when irradiated with microwaves. Solvents such as hexane, toluene,
diethylether, CCl4 do not couple and therefore do not heat with microwave
irradiation, although it is ofcourse possible to use mixtures comprising microwave
active/microwave inactive solvents.
POWER SOURCES
The development of electron tubes including those for the most microwave
range, has been a mature field. Today it is feasible to generate almost any desired
power level for microwave frequencies of practical interest limited only by costs.
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Power Sources in the millimeter wave rang are mostly in the category of
extended interaction Klystrons or narrow band backward wave oscillators. They
are quite expensive and suffer from low life and efficiency. The most dramatic
evolution of a microwave power is that of the cooker magnetron for microwave
ovens. These tubes generate well over 100 watt 2450 MHz into a matched load
and exhibit a tube efficiency on the order of 70%. It is feasible to utilize a number
of such tubes to generate large total power eq. 25 or 50 KW.
APPLICATION IN ORGANIC SYNTHESIS
The first application of microwave oven in organic synthesis began very
recently in the first experiments, Gedye and then Giguere, provided evidence
for dramatic accelerations in some classical organic reactions and these were
described to temperature and pressure effects, when performed in closed teflon
vessels. Since solvents were used in these experiments, some problems with
safe operation appeared and explosion of solvent free reactions to solve these
problems and to facillitate the scale up of preparative runs.
Three types of solvent free procedures can be coupled with microwave
activation.
1. Reaction between heat reactants, needing at least one polar molecule, as
liquid-liquid or liquid solid systems. In this later case, reactions presumbly
occur at the interface due to absorption of the liquid reactant at the surface
of the solid one.
2. Reaction between supported reagents on solid mineral supports in <<
dry media >> by impregnation of compounds on alumina, silicas or clays.
3. Phase Transfer Catalysis (PTC) conditions in the absence of organic solvent,
i.e. when a liquid reagent acts both as a reactant and an organic phase.
This last methodology can be improved under sonochemical activation.
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Microwave constitutes very original procedure for heating materials, clearly
different from the classical ways. Their main advantages derive from the almost
instantaneous "in core" heating of materials, in an homogeneous and  selective
manner. Especially those with poor neat conduction properties. This technique
proves to be exellent in case where traditional heating  has a fow efficiency
because of poor heat transmission and hence local overheating is a major
inconvenience.
The main interests can thus be listed as the rapid transfer of energy into
the bulk of the reaction mixture, without inertia since only the product is heated
and the case of utilization. Furthermore, as the depth of penetration in materials
in of the same order of magnitude as the wavelength, microwaves interact with
substance of apprecialble thickness (about 10 cm).
Sucessfully leading to the path way from non traditional approach to the
experimental setup of organic reactions, the concept of "Microwave Induced
Organic Reaction Enhancement" (MORE) chemistry has been utilized for rapid
and efficient synthesis of pyrazolines which is described as under.
PART - I : STUDIES ON PYRAZOLINES BY CONVENTIONAL AND
MICROWAVE INDUCED SYNTHESIS
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The use of domestic microwave oven in this regard is now a well established
procedure in MORE633 (Microwave Induced Organic Reaction Enhancement).
It has been reported that the rate of variety of organic reaction such Diels-
Alder634,635, Claisan reaction 636,637, oxidation638-640, reduction641,
diacetylation642,643, deacetylation644, esterif ication645, hydrolysis of
esters646,647, Doener condensation648, Knoevenagel condensation649 could
be enhanced by microwave irradiation.
Recent days, domestic microwave oven is useful to prepare isoflavons650,
formazans651, chalcones652, quinazol inones653, benzofurans654 and
pyrazolines655-658. The name reaction such as Biginell i659, Prins660,
Cannizzaro661 and cross  Cannizzaro662,  Michael  addi t ion663,  Fr ies
migration664, Wolfkishner reduction665, Gould Jacobs reaction666, Backmann
reaction667, Tendem-Fries668, Aldol669 can also be performed by domestic
microwave oven.
As a part of ongoing research towards the non traditional approach to the
experimental setup of organic reaction, the concept of microwave enhanced
reaction has been utilized for rapid and efficient synthesis of 1-N-Acetyl-3-aryl-
5-[1'N,3'-diphenyl-4'-pyrazolyl]-pyrazolines. LG domestic microwave oven is
used as a microwave irradiation source and compared in terms of yield and
reaction period and have been cited in Table No. 12a.
SECTION - I : SYNTHESIS AND BIOLOGICAL EVALUATION OF
1N-ACETYL -3 -ARYL -5 - [1 'N ,3 ' -D IPHENYL -4 ' -
PYRAZOLYL]-PYRAZOLINES
SECTION - II : MICROWAVE INDUCED AN EXPEDITIOUS




SYNTHESIS AND BIOLOGICAL EVALUATION OF 1N-ACETYL-3-ARYL-
5-[1'N,3'-DIPHENYL-4'-PYRAZOLYL]-PYRAZOLINES
Pyrazolines are endowed with valid antimicrobial activities. Looking at their
versatile therapeutic importance and with an aim to getting better drug, it was
considered worthwhile to synthesise some new pyrazolines. The preparation of
1N-Acetyl-3-aryl-5-[1'N,3'-diphenyl-4'-pyrazolyl] pyrazolines (XII) have been
undertaken by cyclocondensation of chalcone of type (I) with hydrazine hydrate
in glacial acetic acid.
The constitution of the synthesised products have been characterised using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy
and mass spectrometry also. In mass spectrometry the m/z value indicate the
molecular weight, i.e. when R=p-Anisyl, molecular weight=436, m/z=437 (m+1).
All the compounds have been also evaluated for their antibacterial activity
towards Gram positive and Gram negative bacterial strains and antifungal activity
towards Aspergillus niger at a concentration of 40 µg/ml. The biological activity
of the synthesised compounds have been compared with standard drugs. Some
compounds have been found to have good and equivalent activity as compared
















IR SPECTRAL STUDY OF 1N-ACETYL-3- (p -TOLYL) -5 - [1 'N,3 ' -DIPHENYL-
4'-PYRAZOLYL]-PYRAZOLINE
I
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C-H str. (asym.) 2929 2975-2950 670
C-H str. (sym.) 1421 1470-1435 "
C-H def. (asym.) 1359 1390-1350 "
Aromatic C-H str. 3060 3090-3030 671
C=C str. 1504 1520-1480 "
C-H i.p. def. 1112 1125-1000 "
C-H o.o.p. def. 794 835-800 "
Pyrazole C=N str. 1602 1640-1600 673
moiety C-N str. 1228 1230-1020 "
Pyrazoline C=O str. 1654 1705-1650 671
ring C=N str. 1062 1125-1000 "
















































PMR SPECTRAL STUDY OF 1N-ACETYL-3-p-ANISYL-5- [1 'N,3 ' -DIPHENYL-
4'-PYRAZOLYL]-PYRAZOLINE
Internal Standard : TMS; Solvent : CDCl3 ; Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity Inference J Value
No. (δ ppm) of Protons In Hz
1 2.44 3H singlet -COCH3 -
2 3.03-3.1 1H quartet CHj -
3 3.55-3.64 1H quartet CHk -
4 3.83 3H singlet Ar-OCH3 -
5 5.85-5.9 1H quartet CHl -
6 6.88-6.91 2H doublet CH bb' J=8.9
7 7.22-7.26 1H multiplet CHf -
8 7.27-7.46 5H multiplet CHa -
9 7.59-7.62 2H doublet CH cc' J=8.9
10 7.64-7.69 2H doublet CHeg -











































































































































S B -  3
EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 1N-ACETYL-3-ARYL-
5-[1'N,3'-DIPHENYL-4'-PYRAZOLYL]-PYRAZOLINES
[A] Synthesis of N-Phenylaminophenyl-α-methyl-phenyl azomethine
See [A] Part-I, Section-I (A).
[B] Synthesis of 1N,3-Diphenyl-4-formyl pyrazole
See [A] Part-I, Section-I (B).
[C] Synthesis of 1-(p-Anisyl)-3-[1',N,3-diphenyl-4'-pyrazolyl]-2-propene-1-one
See [A] Part-I, Section-I (C).
[D] Synthesis of 1N-Acetyl-3-(p-Anisyl)-5-[1'N,3'-diphenyl-4'-pyrazolyl]-
pyrazoline
A mixture of 1-(p-Anisyl)-3-[1'N,3'-diphenyl-4'-pyrazol]-2-propene-1-one
(3.8 g, 0.01 M), hydrazine hydrate (2 g, 0.04 M) in  and 30 ml. glacial acetic
acid was refluxed for 12 hrs. The solution was poured into crushed ice. Product
was isolated and crystallised from DMF - Methanol. Yield, 3.4 g (78%),
m.p. 180oC.  (C27H24N4S2; Requires C, 74.31; H, 5.50; N, 12.84%; found :
C, 74.26; H, 5.44; N, 12.76%). TLC solvent system Ethyl acetate : Hexane (4:6).
Similarly, other pyrazolines were prepared The physical data are recorded
in Table No. 12. Antimicrobial testing was carried out described in [A] Part - I,
























12a C6H5- C26H22N4O 406 204 0.56 94 13.78 13.73
12b 4-Br-C6H4- C26H21N4OBr 485 196 0.49 80 11.54 11.53
12c 4-Cl-C6H4- C26H21N4OCl 440.5 178 0.63 83 12.71 12.70
12d 4-F-C6H4- C26H21N4OF 424 208 0.57 77 13.20 13.17
12e 4-CH3-C6H4- C27H24N4O 420 149 0.50 82 13.32 13.30
12f 4-OCH3-C6H4- C27H24N4O2 436 180 0.65 78 12.84 12.80
12g 2-OH-C6H4- C26H22N4O2 422 183 0.58 80 13.26 13.21
12h 4-OH-C6H4- C26H22N4O2 422 210 0.70 75 13.26 13.23
12i 4-NH2-C6H4- C26H23N5O 421 173 0.68 79 16.62 16.64
12j 3-NO2-C6H4- C26H21N5O3 451 186 0.59 75 15.51 15.53
12k 4-NO2-C6H4- C26H21N5O3 451 113 0.71 74 15.51 15.49
12l 2-C4H3O- C24H20N4O2 396 98 0.63 80 14.13 14.11
12m 2-C4H3S- C24H20N4OS 412 114 0.75 71 13.58 13.57
*TLC Solvent System : 12a, 12b, 12c, 12d, 12h, 12j : Acetone : Benzene (2 : 8).


































B.mega 17 22 11 18 12 15 19 13 16 20 23 14 19 23 22 24 25 0
s.aureus 13 12 20 16 14 14 21 12 11 15 22 14 17 22 23 17 24 0
E.coli 17 16 11 23 14 15 17 12 20 13 15 19 18 21 21 23 19 0
P.vulgaris 13 11 17 10 19 17 20 16 13 17 14 13 12 15 18 17 20 0
A.niger 20 11 23 12 13 18 14 15 19 17 16 21 20 0 0 0 0 25










COMPARATIVE STUDY OF ANTIMICROBIAL ACTIVITY WITH KNOWN ANTIBIOTICS
[B]
PART-I
Section - I : Antimicrobial activity of 1N-Acetyl-3-aryl-5-[1'N,3'-diphenyl-4'-pyrazolyl]-pyrazolines
12b (22) 12c (20) 12d (23) 12e (19) 12c (23)
12j (23) 12g (21) 12i (20) 12g (20) 12l (21)
12k (23) 12k (22)
Ampicillin 23 22 21 15 -
Amoxicillin 22 23 21 18 -
Norfloxacin 24 17 23 17 -
Penicillin 25 24 19 20 -
Greseofulvin - - - - 25
B. mega S. aureus E. coli P. vulgaris A. niger
Antifungal activity
Zone of inhibition in m.m.
Antibacterial activity





MICROWAVE INDUCED AN EXPEDITIOUS SYNTHESIS OF
1 N -A C E T Y L - 3 -A RY L - 5 - [ 1 ' N , 3 ' -D I P H E N Y L - 4 ' -P Y R A Z O LY L ] -
PYRAZOLINES
As a part of our programme directed towards non traditional approach to
the experiment setup of organic reactions, the concept of "Microwave Induced
Organic Reaction Enhancement" chemistry has been utilised for rapid and
efficient synthesis of some 1N-Acetyl-3-aryl-5-[1'N,3'-diphenyl-4'-pyrazolyl]
pyrazolines (XII) by the condensation of chalcone of type (I) and hydrazine
hydrate in glacial acetic acid.
The constitution of the synthesised products have been characterised using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy
and mass spectrometry also. In mass spectrometry the m/z value indicate the
molecular weight, i.e. when R=p-Anisyl, molecular weight=436, m/z=437 (m+1).
All the compounds have been also evaluated for their antibacterial activity
towards Gram positive and Gram negative bacterial strains and antifungal activity
towards Aspergillus niger at a concentration of 40 µg/ml. The biological activity
of the synthesised compounds have been compared with standard drugs. Some
compounds have been found to have good and equivalent activity as compared
to the known antibiotics recorded on Page No. 194.
The spectral and antimicrobial activity of the product obtained by
microwave method are found to be identical. The yields of the products obtained















R = ArylType (XIII)
EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 1N-ACETYL-3-ARYL-
5-[1'N,3'-DIPHENYL-4'-PYRAZOLYL]-PYRAZOLINES
[A] Synthesis of N-Phenylaminophenyl-α-methyl-phenyl azomethine
See [A] Part-I, Section-I (A).
[B] Synthesis of 1N,3-Diphenyl-4-formyl pyrazole
See [A] Part-I, Section-I (B).
[C] Synthesis of 1-(p-Anisyl)-3-[1',N,3-diphenyl-4'-pyrazolyl]-2-propene-1-one
See [A] Part-I, Section-I (C).
[D] Synthesis of 1N-Acetyl-3-(p-Anisyl)-5-[1'N,3'-diphenyl-4'-pyrazolyl]-
pyrazoline
A mixture of 1-(p-Anisyl)-3-[1'N,3'-diphenyl-4'-pyrazolyl]-2-propene-1-one
(3.8 g, 0.01 M), hydrazine hydrate (2 g, 0.04 M) and glacial acetic acid  (1-3 ml)
was irridiated longer than 1 min. at a time to avoid boiling of solvent. After the
completion of reaction the reaction mixture was cooled and poured into cold
water. The product was isolated and crystall ized from DMF - Methanol.
Yield, 3.4 g (78%), m.p. 180oC.  (C27H24N4S2; Requires C, 74.31; H, 5.50;
N, 12.84%; found : C, 74.26; H, 5.44; N, 12.76%). TLC solvent system Ethyl
acetate : Hexane (4:6).
Similarly, other pyrazolines were prepared The physical data are recorded
in Table No. 12. Antimicrobial testing was carried out described in [A] Part - I,
Section (D). The zone of inhibition of test solutions are recorded in Graphical
Chart No. 12.
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TABLE NO. 12a  :COMPARISION OF CONVENTIONAL METHOD AND
MICROWAVE ENHANCED SYNTHESIS OF PYRAZOLINES
12a C6H5- 10 78 4 84 204
12b 4-Br-C6H4- 12 76 6 80 196
12c 4-Cl-C6H4- 11 77 6 83 178
12d 4-F-C6H4- 10 69 6 77 208
12e 4-CH3-C6H4- 11 74 5 82 149
12f 4-OCH3-C6H4- 12 72 5 78 180
12g 2-OH-C6H4- 10 73 5 80 183
12h 4-OH-C6H4- 12 70 6 75 210
12i 4-NH2-C6H4- 11 69 4 79 173
12j 3-NO2-C6H4- 12 70 4 75 186
12k 4-NO2-C6H4- 12 68 5 74 113
12l 2-C4H3O- 10 72 6 80 98
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